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General introduction 
 
Sacral neuromodulation (SNM) therapy is a therapy that comprises the 
electrical stimulation of the sacral nerves that innervate most organs and 
structures of the pelvis including the bladder, urethral sphincter and pelvic 
floor muscles. For this therapy electrodes are placed at the level of the third 
sacral nerve (S3) and are connected to an implantable battery that is known 
as an Implantable Nerve Stimulator (INS). This treatment was developed in 
the early 1980s and since the FDA approval in 1997, an increasing number of 
patients have been treated with SNM. Within urology, SNM is an accepted 
treatment option for patients with idiopathic overactive bladder syndrome 
(I-OAB) or non-obstructive urinary retention and who are refractory to 
conservative treatment.  
 
Idiopathic overactive bladder syndrome 
Idiopathic overactive bladder syndrome (I-OAB) is a combination of urinary 
symptoms and is defined as urgency with or without urgency-incontinence, 
usually with frequency and nocturia [1]. The estimated prevalence is 
between 12-17% of which a third experiences urgency urinary incontinence 
(UUI) [2-5]. This syndrome significantly impacts on the patient’s quality of 
life (QoL) and the costs for I-OAB management are estimated between 250 
million and 4.2-billion euro in selected European countries [6-9]. Treatment 
of patients with I-OAB is complex and international guidelines suggest 
lifestyle interventions, pelvic floor muscle training, bladder retraining and 
medication (anti-muscarinics) as first line treatment options [1, 10, 11]. PTNS 
(Percutaneous Tibial Nerve Stimulation) is a non-surgical treatment option 
that has recently been included in the European Association of Urology 
Guidelines for Incontinence. It is considered as a possible treatment option 
for improvement of urgency urinary incontinence in women, but not in men, 
who have not benefited from antimuscarinic medication [10].   
When first line therapy options fail or are unacceptable for patients, surgical 
options are available. These include SNM therapy, Botulinum toxin injection 
in the bladder (BTX) and bladder augmentation (Figure 1).  SNM and BTX 
therapies are considered to be minimally invasive and should be tried first 
before bladder augmentation. Starting with SNM or BTX is usually based on 
the experience of the clinic and personal preference as well from the 
patient’s perspective as from the doctor’s point of view. There is no 
prospective study yet comparing these two treatment options and the long-
term cost effectiveness is still unclear.  
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Non-obstructive urinary retention  
Urinary retention is defined as the inability to empty the bladder completely. 
The causes of urinary retention can be divided into (mechanically) 
obstructive urinary retention and non-obstructive urinary retention. Non-
obstructive urinary retention includes inability of outlet (e.g. sphincter) 
relaxation, detrusor underactivity or a combination of both, and can be 
neurogenic or non-neurogenic. Obstructive urinary retention is a mechanical 
or anatomical obstruction of the bladder outlet, such as a tumour, stone or 
urethral strictures, and can usually be treated by medication or by surgically 
removing the obstruction. However, few treatment options are available for 
non-obstructive urinary retention. Non-obstructive urinary retention (when 
not pharmacotherapeutically induced) is usually treated conservatively with 
intermittent self-catheterization or placement of an indwelling catheter 
suprapubically or transurethrally. SNM is a minimally invasive treatment 
option for patients with non-obstructive urinary retention. For practical 
purposes non-obstructive non-neurogenic urinary retention will be referred 
to as non-obstructive urinary retention.      
 
Figure 1: Algorithm derived from ‘evidence-based’ recommendations of the ICI from 2008 
Urgency  
Incontinence 
• Neuromodulation (Grade A) 
• Botulinum toxin (Grade C) 
• Bladder augmentation (Grade C) 
Specialized management of Urinary Incontinence 
• Correct anatomic BOO 
• α-blockers (male) 
• 5α-reductase inhibitors 
(male) 
• Antimuscarinic  
With bladder outlet 
obstruction (BOO) 
• Intermittent 
catheterization 
• Antimuscarinic  
With underactive 
detrusor 
Chapter 1 
 
 12 
Sacral neuromodulation therapy 
Working mechanism  
The precise mechanism of action of SNM therapy is still not entirely clear. 
SNM has been proven to work in patients with a seemingly contradictory 
condition, namely overactive bladder and underactive bladder, and the 
treatment comprises of continuous stimulation. This suggests that SNM 
affects the ‘neuroaxis’ and restores the balance between excitatory and 
inhibitory regulation at various locations within the peripheral and central 
nervous system [12]. The exact sites or pathways that are modulated are still 
unknown, however, several neurophysiological data suggest an effect on the 
afferent pathway. One study showed a reduction in the sensory threshold of 
the bladder during SNM treatment, but not of the urethra, which suggests 
afferent nervous system involvement through the pelvic plexus [13]. 
Another study showed a significant decrease in pudendal somatosensory 
evoked potential latency during SNM [14]. Studies with PET-scans on 
patients with SNM showed activation changes in the brain that also supports 
the hypothesis that SNM works by modulation through afferent nerves. One 
study with PET-scans compared acute with chronic SNM treatment on 
patients with overactive bladder and showed activation differences in the 
associative sensory cortex, premotor cortex and the cerebellum [15]. The 
other study with PET-scans compared patients with non-obstructive urinary 
retention with and without SNM and showed activation differences in the 
midbrain and limbic cortical regions [16].  
 
Treatment protocol 
Before implanting the INS (Implantable NeurStimulator), a screening test is 
performed to assess the clinical efficacy of sacral nerve stimulation. There 
are two screening test protocols.  
The first, known as Percutaneous Nerve Evaluation (PNE), uses a non 
anchored test lead placed into the S3 foramen and connected to an external 
battery, also known as an external pulse generator (EPG). The test period 
extends between 4 and 14 days after which the test lead is removed. The 
procedure is usually done in an outpatient setting. The overall response rate 
for PNE is around 55% [17, 18]. Lead migration is considered the main factor 
leading to false negative results [19, 20].  
The definitive lead electrode has self-anchoring tines that reduce the risk of 
migration, and is called the tined lead. The second protocol for screening 
uses this tined lead for testing. The lead is placed into the S3 foramen 
usually under general anaesthesia, although local anaesthesia is possible in 
an outpatient setting. Correct positioning is guided with fluoroscopy and the 
lead is subcutaneously connected to a temporary extension lead that exits 
General Introduction, Aim and Outline of the Thesis 
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the skin and is connected to an EPG. This procedure, which is known as the 
first stage tined-lead test (FSTLP), enables test periods up to three to four 
weeks. If the patient has a good response during the test, the present lead is 
connected to an INS, which would be the second stage. This procedure is 
performed under local or general anaesthesia. Because of the decreased risk 
of migration and the longer test duration, this test has a higher response 
rate. According to a study by Kessler et al, prolonged screening with the 
tined lead has a response rate of 67% compared to 43% during PNE testing 
[21]. The costs for the test protocol with the tined leads are much higher 
compared to the PNE test. Currently the use of either one of the two 
screenings option is arbitrary.  
Both batteries, the INS and EPG, can have a variety of settings. The electrical 
waveform that the battery produces is a square wave pulse. The pulse-rate 
can be set between 2.1 and 130 Hz and the pulse-width between 60 and 450 
µs. Furthermore, the amplitude can be changed from 0.05 to 10.55 V. Most 
centres that treat patients with SNM commonly use pulse rates between 10 
and 16 Hz and pulse-width of 120µs [17, 22, 23]. These settings are mostly 
empirical. Data on the effect of the different parameters is still lacking and 
therefore the potential effect of pulse changes was one of the topics of our 
research for this thesis. 
 
Effectiveness for I-OAB 
There is convincing evidence for the success of SNM therapy among patients 
with I-OAB who are refractory to conservative treatments. Three 
randomised controlled trials (two on patients with urgency incontinence and 
one on patients with urgency frequency) and many articles on long-term 
observational studies have been published [17, 18, 23-28]. In all reported 
studies, clinical success is defined as a > 50% improvement in one of the 
relevant urinary voiding parameters. Good clinical response is reported 
between 64 and 88% of all patients. All parameters reported showed 
significant improvement compared to the placebo group: a 23-46% decrease 
in the number of voids per day, 44-77% increase in the average voided 
volume, 56-90% decrease in incontinence episodes per day, 64-100% 
decrease in pads and 39% increase in maximum cystometric capacity (Table 
1).  
A five year follow-up study on 121 patients with refractory I-OAB showed 
persistence of the clinical success in the long term: 84% of the patients with 
urgency incontinence and 71% of the patients with urgency/frequency 
which had a successful outcome one year after implantation continued to 
have a successful outcome after five years [26]. A study on the tined lead 
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procedure in 21 patients with I-OAB showed around 90% clinical success 
after an average of 15.5 months[28].  
Satisfaction and quality of life scores after SNM have also been studied. 
Cappellano et al. showed a significant improvement in the quality of life 
score in patients with urgency incontinence who underwent SNM, with a 
mean score between 34 and 76 [29]. At 18 months follow-up patients were 
asked whether they would undergo this treatment again. Ninety percent 
responded yes and 100% would recommend it to a relative or friend. Foster 
et al. asked 49 patients with urgency incontinence on their satisfaction with 
SNM treatment. The majority of the patients, 84% and 80% respectively, 
were “satisfied” and would “do it all over again” [30]. Little is known about 
the daily experience or daily use of SNM. 
 
Table 1. Short-term results of treatment with sacral neuromodulation or with placebo among 
patients with overactive bladder. 
  
FU 
period 
month
s 
Overall 
improv
ement 
# of 
voids 
reductio
n per 
day 
Increas
e in 
voided 
vol 
IE 
improv
ement 
per day 
Proportio
n of group 
with 100% 
continenc
e 
Improve
ment in 
# pads/ 
day 
Improv
ement 
MCC 
RCT’s 
Weil et al. 6        90% 56% 92% 39% 
Schmidt et al. 6        73% 47% 82%   
Hassouna et al. 12  88% 46% 77%         
Observational studies 
Kerrebroeck et 
al. 49    23% 79% 56%   64%   
Voskuilen et al.  64.2  64%             
Sutherland et 
al.  22  69% 35%   88% 50% 100%   
Voskuilen et al. 15.5  80% 38% 44% 65%       
Hijaz et al. 16  75%             
*significant compared to placebo, FU: follow-up, IE: incontinence episodes, MCC: maximum cystometric 
capacity 
 
Effectiveness for retention 
The evidence of SNM for non-obstructive urinary retention is based on one 
randomised controlled trial and several cohort studies on both the short and 
long-term follow-up [22, 26, 28]. Good clinical response, defined as more 
than 50% improvement in bladder diary variables, such as catheter volume 
per catheterisation, number of catheters per day, total catheter volume per 
day, maximum catheter volume per day and number of voids per day, is 
reported between 55% and 90%.  
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In the randomised controlled trial all parameters reported showed 
significant improvement compared to the placebo group: an average of 86% 
decrease in the catheter volume per catheterization per day, 64% decrease 
in number of catheterisations per day, 82% decrease in total catheter 
volume per day, 85% decrease in maximum catheter volume per day and 
224% increase in number of voids per day [22].  
SNM is an effective treatment for non-obstructive urinary retention on the 
long-term. A study with a 5 year follow-up showed persistence of the clinical 
success: 78% of the patients with non-obstructive urinary retention which 
had a successful outcome one year after implantation continued to have a 
successful outcome after five years [26]. Another study on the tined lead 
procedure showed, in 9 patients with non-obstructive urinary retention, 90% 
clinical success after an average of 15.5 months [28]. 
SNM has a positive impact on the satisfaction and quality of life scores. In a 
quality of life study among patients with non-obstructive urinary retention 
treated with SNM, significant improvement on the physical, social and 
psychological levels was shown [31].  
 
Table 2. Most frequent adverse events associated with sacral neuromodulation therapy 
  
Pain at 
implant 
site 
Lead 
migration Other pain 
Bowel function 
disturbance Infection 
Weil et al. 42% 21% 18% (leg) 5%   
Schmidt et al. 33% 13%   5% 4% 
Hassouna et al.       4%   
Kerrebroeck et 
al. 19% 5% 7.9% (lead site) 7% 8% 
Voskuilen et al. 28% 7% 
43% (pain or 
discomfort)   4% 
Sutherland et al. 15%     5% 10% 
Voskuilen et al. 7% 3% 3% (leg stimulation)     
Hijaz et al. 3% 1%     5% 
 
Adverse Events 
Adverse events are usually related to the implant procedure, the presence of 
the implant or undesirable sensations or effects due to the electrical 
stimulation. The most common adverse event reported is pain at the 
implantation site. The occurrence in most studies varies between 3 to 42% 
(Table 2) [18, 23-28, 32]. Other adverse events reported are lead migration 
(1 to 21%), bowel dysfunction (4 to 7%) and infection (4 to 10%). Technical 
improvements throughout the years have significantly decreased the 
incidence of adverse events. Two important improvements were the 
introduction of tined leads (leads with hooks) and the gluteal, instead of 
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abdominal, placement of the INS. Ever since, both the incidence of adverse 
events and the reoperation rate per implanted patient has decreased (Figure 
2) [27].  
 
 
Figure 2. Average number of adverse events and surgical revision per implanted patient 
[25] 
 
 
The majority of adverse events do not require surgical intervention. 
Decreased efficacy because of electrode migration and undesirable 
stimulation can generally be solved by reprogramming of the INS. A 
retrospective analysis among 83 implanted patients with a reduced response 
or complications, such as pain at the INS-
could be conservatively helped [25]. Furthermore, the incidence of adverse 
events is lower with the new tined leads in comparison with non
(respectively 28% and 73%) [25]. A study among 235 patients confirmed that 
tined leads migrate less often, with an incidence of 2.1% 
data indicate that the further development and optimisation of sacral 
neuromodulation limits the risk of adverse events. 
 
 
site, showed that 18% of the cases 
-tined leads 
[33]. The available 
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Aim and outline of this thesis  
The aim of this thesis is to further improve or optimise SNM treatment in 
Urology. The first part of this thesis deals with the long-term efficacy, 
satisfaction and experience with SNM. In the second part SNM will be 
compared with a different treatment option in a cost-effectiveness study. 
The third part of this thesis discusses the optimal way of selecting and 
treating patients by comparing two screening methods and by changing the 
battery parameters. 
 
Chapter 1 presents a general introduction to the thesis and discusses the 
aim and outline. 
Chapter 2 describes a single centre study that assessed the long-term 
efficacy and adverse events of SNM with TLP.   
In Chapter 3 a study is described which evaluates the long-term satisfaction 
of patients on SNM therapy and their daily experiences with the treatment.  
Chapter 4 is an overview of SNM and BTX treatment in the second-line 
management of adults with I-OAB, based on the available clinical evidence 
concerning the efficacy and safety.   
Chapter 5 provides a cost-effectiveness study comparing either starting 
treatment with SNM or BTX in patients with refractory I-OAB from a societal 
perspective. 
In Chapter 6 a study is described in which the response rate of the two types 
of screening options to determine eligibility for SNM therapy, FSTLP and PNE 
test, are compared.  Chapter 7 presents the results of a pilot study in which 
the impact of pulse rate changes (5.2Hz–10Hz–21Hz–40Hz) is evaluated 
among patients with suboptimal response to SNM therapy on clinical 
outcome, the sensory responses and SNM-related pain symptoms.   
Chapter 8 presents the general discussion and future perspectives on sacral 
neuromodulation therapy 
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Abstract 
Aims: To compare the patient’s response rate to the Percutaneous Nerve 
Evaluation test (PNE) and the 1st stage tined-lead placement test (FSTLP) for 
sacral neuromodulation therapy (SNM).  
 
Methods: Single centre study on patients with refractory idiopathic 
overactive bladder syndrome (OAB) or non-obstructive urinary retention, 
screened with both PNE and FSTLP. Patients were followed prospectively 
and their response rate based on bladder diary after PNE was compared to 
that after FSTLP. More than 50% improvement in at least two relevant 
urinary symptoms was considered a positive response. A Wilcoxon paired 
test was done to compare the rates of the two screening options and logistic 
regression to determine possible associations. A follow-up was conducted to 
determine the long-term failure rate.    
 
Results: One hundred patients were included (82 female, 69 OAB). The mean 
age was 55 years (SD 13). The positive response rate on PNE was 47%. FSTLP 
showed a 69% positive response rate, which was negatively related to age. 
The 22% gain in positive response was statistically significant (p<0.001) and 
positively associated with female gender and younger age. All 69 patients 
with a positive response to FSTLP received SNM treatment. Failure rate after 
an average of 2 years was 2.9%.  
 
Conclusions: This study suggests that FSTLP may be a more sensitive 
screening method than PNE to identify patients eligible for SNM therapy, 
warranting randomized trials.  
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Introduction 
Sacral Neuromodulation (SNM) is a well established therapy for patients 
with idiopathic overactive bladder syndrome (OAB) or non-obstructive 
urinary retention (retention). The long-term success rate varies between 56 
and 71% depending on the underlying bladder dysfunction [1, 2]. In order to 
achieve optimal results, accurate screening tests are crucial. Patients 
considered eligible for SNM therapy are selected based on their response to 
a test period of SNM with an external neurostimulator. Currently two 
different methods are used to screen patients for their response to SNM: 
the Percutaneous Nerve Evaluation test (PNE) which uses a standard 
electrical wire electrode, and the first stage tined-lead placement test 
(FSTLP) which uses a special electrode with small anchors to reduce the risk 
of lead migration [3]. Patients who show more than 50% reduction in urinary 
symptoms during this test period are considered good candidates for 
definitive SNM therapy.  
Currently only one study evaluated the difference in response rate to PNE 
and FSTLP [4]. In 30 urgency incontinent patients, they showed that 6 out of 
13 patients in the PNE group showed a successful response compared to 15 
out of 17 patients in the FSTLP group. Therefore more patients received the 
definitive implant after FSTLP than after PNE [4].   
The primary goal of this study is to compare the response rate of FSTLP with 
PNE test to determine eligibility for SNM therapy among patients with either 
idiopathic OAB or non-obstructive urinary retention. The secondary goal was 
to evaluate whether age, gender, type of bladder complaint (OAB or 
retention) and lead position have an effect on the results. Finally the long-
term SNM failure rate of patients selected trough FSTLP was evaluated to 
determine the validity of the screening tests.  
 
Materials and Methods 
This single-centre prospective observational study included patients with 
idiopathic OAB or non-obstructive retention, refractory to conservative 
therapy, and was conducted in accordance to the ethical committee 
guidelines of the local university hospital. 
All patients were first screened with the PNE (30576SC, Medtronic, 
Minneapolis, Inc.) and afterwards with the FSTLP (3889-28, Medtronic Inc.). 
All procedures were performed under local anaesthesia.  The PNE procedure 
was performed according to the method described by Jonas and coworkers 
[5]. Electrode position was determined based on the clinical motor and 
sensory response towards stimulation. Following the PNE procedure an X-
ray was taken to determine the position of the lead. At the end of the 
testing period patients were asked if they still felt the electrical sensation in 
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the correct area. If not, the electrode position was evaluated by X-ray and in 
case of dislocation the PNE procedure was repeated. 
The FSTLP was performed according to Spinelli et al [6]. During the FSTLP 
fluoroscopy was used to determine proper electrode position in the third 
sacral foramen. The response to the PNE and FSTLP was assessed based on 
the bladder diary data before (baseline) and during the two screening tests. 
PNE was tested for three consecutive days because of the increasing risk of 
lead migration after this period. For the baseline and PNE evaluation, 
patients were asked to complete the diary for at least three days and for 
FSTLP for at least one week. However for FSTLP only the data of the first 
three days were used to match the test duration of PNE.  
Parameters used for patients with OAB were the frequency of voids per day, 
the average voided volume per void and the maximum voided volume. For 
the OAB patients with urinary incontinence, the average frequency of 
leakages per day, the severity of leakage and the average number of pads 
used per day were additionally noted. For patients with non-obstructive 
retention the average voided volume per void was noted, together with the 
post void residual urine, determined by catheterization. A positive response 
was defined as at least 50% improvement in two or more relevant 
parameters. 
Failure rate was determined by reviewing patient’s chart in order to 
establish the validity of FSTLP among patients who received a definite SNM 
implant. Since this study was one of the first to analyze FSTLP test results for 
sacral neuromodulation therapy it was difficult to perform a power analysis 
not knowing the strength of the associations of the predictors used in 
analysis in advance. Therefore a tentative number of 100 patients was used 
to gauge the sensibility of the tests. Test results were cross-tabulated in a 2-
by-2 table using Kappa (κ) as a measure of agreement and the Wilcoxon test 
to test differences. Three dichotomous outcome measures were first 
analyzed by univariate statistics only: the results of the PNE test, the results 
of the FSTLP test and the results of the difference or potential gain in 
positive result between both tests. Next, a logistic regression analysis was 
done for each of the outcome measures using backward elimination -2 log-
likelihood chi-squares (-2LLχ
2
L) as the searching technique in modeling. 
Predictors used in the analyses were patient’s gender, age, type of 
complaint (OAB or retention) and position of lead (based on X-ray: left or 
right foramen, Sacral foramen position 2, 3, 4 or 5, and depth lead 
(superficial, correct or too deeply placed). First-order interaction effects 
between predictors were tested by the forward selection technique. If age 
had a statistically significant effect, optimal dichotomous categorizing was 
used to determine cut-off points within age. A p-value of less than 0.05 was 
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considered to be statistically significant. All data-analysis was done with 
SPSS-pc version 16.0.  
 
Results 
Between July 2002 to December 2008, in total 100 patients were tested with 
both the PNE and the FSTLP test; 82 were female and 18 male. The mean 
age was 55 years (SD 13). Sixty-nine were diagnosed with OAB and 31 with 
non-obstructive urinary retention.  
Significantly more patients responded positively to the FSTLP test compared 
to the PNE test (Wilcoxon test p<0.001) (table 1). The number of patients 
respectively was 69 for FSTLP and 47 for PNE test. Furthermore, all patients 
that responded positively to PNE, did also respond positively to FSTLP. The 
agreement between the positive responses of both tests was κ=0.57 (95%CI 
0.43-0.71, p<0.001). All 69 patients who had a positive response to the 
FSTLP test received a definite SNM implant. At a mean follow-up of 26 
months (SD 18), therapy failed in only 2 patients (2.9%). Both were female 
OAB patients who had a positive response to both PNE and FSTLP. One 
failure was because of lack of efficacy and one because of pain at battery 
site requiring removal of the implanted device.  
For the PNE test neither age, gender nor type of complaints were 
univariately related to a positive outcome of the test (table 1). X-rays taken 
post PNE procedure showed that 61 had the lead placed in a correct depth 
while 13 had it placed too superficial and 26 too deep. A total of 46 patients 
had their lead placed in the S3 foramen, while 3 had it in S2, 36 on S4, 8 on 
S5 and 7 lateral of the sacral bone. Multivariate analysis also showed no 
significant relationship between a positive outcome and localisation and 
depth of the electrode.  
For FSTLP, a successful response was negatively related to the patient’s age 
(univariate OR=0.96, 95%CI: 0.93-1.00, p=0.036), however not to the type of 
complaint. The optimal cut off point for age was 65 years (OR=0.33, 95%CI: 
0.13-0.87, change in -2LLχ
2
=5.07, p=0.024) (Table 1), that is, patients older 
than 65 years of age had a significantly lower probability to respond 
positively to FSTLP. In the multivariate analysis corrected for age, neither 
gender or type of complaint was related to a positive FSTLP response.  
Analysis of the group of 22 patients who responded successfully to FSTLP 
after failing the PNE test showed that relatively more patients were younger 
than 45  years of age (OR=0.29, 95%CI: 0.10-0.87 (-2LLχ
2
 =4.70, p=0.030) and 
relatively more patients were female: only 1 (6%) of the 18 males versus 21 
(26%) of the 82 females (OR=6.59, 95%CI: 0.80-54.43, -2LLχ
2
L =4.79, p=0.029) 
(Table 3). 
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Table 1. Univariate results for positive response with PNE and FSTLP 
  PNE FSTLP 
Predictors Category N 
% 
pos. χ
2
L 
p-
value OR 
95% 
C.I. OR N 
% 
pos. χ
2
L 
p-
value OR 
95% C.I. 
OR 
  All 100 47         100 69         
Gender Male  18 56 0.64 0.42 -   18 61 0.62 0.43 -   
Female 82 45     0.66 
0.24-
1.84 82 71     1.54 
0.53-
4.44 
Age 
      0.22 0.64 0.99 
0.96-
1.02     4.39 0.036 0.96 
0.93-
1.00 
≤ 65 years  76  50  1.16  0.28  -   76 75 5.07 0.024 -   
> 65 years  24  38      0.60 
 0.23-
1.54 24 50     0.33 
0.13-
0.87 
Type of 
complaint 
Retention 31 45 0.06 0.81 -   31 61 1.22 0.27 -   
OAB 69 48     1.11 
0.48-
2.61 69 73     1.66 
0.68-
4.07 
Lead depth 
position Superficial 13 54 3.81 0.15 1.06 
0.32-
3.51             
Correct 61 53     -              
Too deep 26 31     0.40 
0.15-
1.07             
Lead sacral 
position S2 3 33 2.42 0.66 0.50 
0.04-
5.91             
S3 46 50     -              
S4 36 39     0.64 
0.26-
1.54             
S5 8 63     1.67 
0.36-
7.80             
none 7 57     1.33 
0.27-
6.64             
(-) = reference category; 0=negative, 1=positive response on test. 
 
Table 2. Univariate results for gain in positive response between FSTLP and PNE 
Predictors Category N % pos. χ
2
L p-value OR 95% C.I. OR 
  All 100 22         
Gender Male  18 6 4.35 0.037  -   
Female 82 26     5.85 0.73-46.70 
Age       3.03 0.082 0.97 0.93-1.01 
≤ 45 years 20 40 4.27 0.039 -   
> 45 years 80 18     0.32 0.11-0.92 
Type of 
complaint 
Retention 31 16 0.94 0.33 -   
OAB 69 25     1.70 0.56-5.12 
(-) = reference category 
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Table 3. Final logistic regression model results for gain in positive response on FSTLP after PNE  
Final logistic regression model 
Predictors Category B S.E. p-value OR 95% C.I. OR 
Gender Male    -  
Female 1.89 1.08 0.080 6.59 0.80-54.43 
Age </= 45 years    -  
45 years -1.24 0.57 0.028 0.29 0.10-0.87 
Constant  -2.00 1.09 0.065 0.14  
Significance test in -2LLχ
2
 
Predictors Log likelihood Change in -2LL df Sig. of the change 
Gender -50.56 4.79 1 0.029 
Age -50.52 4.70 1 0.030 
0= negative or positive result on both tests , 1=a  positive response on  FSTLP after a  negative one on PNE,  (-
) = reference category 
 
Discussion 
The PNE test was initially the only method to screen patients for their 
eligibility for sacral neuromodulation. The success rate for this method is 
reported to lie around 48-60% [6, 7], which corresponds with the findings of 
this study. The lead used during this test is a standard electrical wire 
electrode that has the potential to migrate if stresses occur. This may lead to 
false negative responses during the PNE, as shown by Janknegt et al. [8]. 
Eight out of 10 patients that failed PNE after having an initial good effect 
during the test (probably due to migration) were successfully treated with 
SNM therapy with the definitive electrode (which at that time was an 
electrical wire with four electrodes, sutured subcutaneously to minimize 
lead migration). In our study, none of the patients reported having a change 
in the sensitivity to the stimulation, implying that no lead migration had 
occurred. However, since no confirmatory fluoroscopy had been performed, 
hypothetically minor dislocations might have occurred without a change in 
sensation of the stimulation. 
 
In 1997, the two-stage implantation technique was introduced, with the use 
of definite lead for testing. When the test was successful, a pulse generator 
was implanted [8]. Everaert et al. showed that the failure rate for patients 
with an implanted SNM device was lower for a two-staged procedure than 
for a one-stage procedure [9]. In 2002, a new lead was introduced with tines 
or anchors to minimize the risk of migration and soon after the two stage 
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tined lead placement followed [6, 10]. Positive response rates to FSTLP 
ranges from 67 to 88% [3, 4, 11], comparable to the 69% found in this study. 
 
The difference in response rate between PNE and FSTLP could partly be 
attributed to lead migration during the PNE test, although no change in 
sensory response was noted in this study. However the lead location or 
position during the placement may also account for it. In our study, during 
the PNE procedure, anatomical landmarks and motor/sensory responses of 
the bellow and great toe were used to guide electrode placement, 
fluoroscopy was not used to check electrode position. A control X-ray after 
placement showed an incorrect location of position of the PNE electrode in 
some patients, although the sensory and motor responses were noted. 
Analysis showed that neither the depth nor the foramen used were 
statistically related to a positive response to PNE nor to FSTLP after failing 
PNE.     
For patients with urgency incontinence, the positive response-rate with 
sacral neuromodulation has been associated with patient’s age, with older 
patients having a lower chance to achieve complete continence by sacral 
neuromodulation [12].  Our study also shows that age is negatively related 
to a successful outcome of the FSTLP test. Furthermore, among patients who 
failed PNE test, higher age results in a lower probability to respond 
successfully to FSTLP. It is still a matter of speculation why older patients are 
less likely to respond to sacral neuromodulation. Age related changes in the 
bladder and/or neural system may reduce the efficacy of the currently used 
forms of neuromodulation.  
 
In this study female gender was related to a higher probability for success 
with FSTLP after failing PNE. Currently, no data are available to suggest 
gender as a predictive factor for positive response to SNM, and from our 
current setup no clear explanation can be found. Factors as comorbidity, 
previous history of stress incontinence surgery or complaint duration have 
been linked to the outcome on neuromodulation, [12-14] however these 
were not addressed in our study. 
 
The purpose of this study was to compare patient’s response to PNE and 
FSTLP test in a study design where all patients received both tests and 
therefore were their own control group. A limitation of this design is that it 
is not a randomized control study. Although no power analysis was 
conducted, a number of 100 patients were estimated to sufficiently provide 
a reliable comparison. The data from this repeated measure study suggest a 
superior effect of FSTLP compared to PNE. 
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At the moment, there is no consensus concerning the optimal SNM 
screening methods. Therefore, the decision to choose PNE, FSTLP or even 
both as screening depends on the surgeon’s experience. Clearly different 
aspects may influence the choice. PNE placement is faster, the test period is 
shorter, and the procedure is cheaper than FSTLP. On the other hand, FSTLP 
appears to be more effective, has a lower migration rate and it has the 
advantage of ensuring the place where the lead is implanted is effective 
before the battery is implanted. Performing both screening tests in the same 
patient also has some advantages. By performing PNE first, patients who 
experience pelvic floor side effects or worsening of their complaint can be 
identified and excluded. In addition, there is an option to exclude all patients 
who are mentally or even physically unable to cope with the SNM implant. 
Another advantage of doing both techniques is that the amount of stress 
during the TLP might be reduced when the patient already had experienced 
PNE. This may also be beneficial in patients with a reduced coping capability. 
Although our study suggests FSTLP as the most sensitive screening method, 
it is clear that individual tailoring of screening methods may be necessary in 
certain patients, for example in those with coexisting psychological 
problems. 
 
Conclusions 
In this study more patients had a positive response to FSTLP than PNE (69% 
vs. 47%). The difference or gain was statistically significant (p<0.001) and 
was negatively affected by male gender and higher age. Logistic regression 
of the PNE found no predictors for positive response. However the same 
analysis for the FSTLP showed a negative effect of age. All patients who had 
a positive response to FSTLP received the SNM treatment. The failure rate of 
these patients after an average of 2 years was 2.9%. In conclusion, this study 
suggests that FSTLP may be a more sensitive screening method than PNE to 
identify patients eligible for SNM therapy, warranting randomized trials.  
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Abstract 
Purpose: We evaluated the effect of pulse rate changes on the clinical 
response and stimulation related pain symptoms in sacral neuromodulation 
treatment.  
 
Materials and methods: This pilot study we evaluated the effect of 4 
different pulse rates, including 5.2, 10, 21 and 40 Hz, in patients with a 
suboptimal response to sacral neuromodulation. The effect of each 
frequency was evaluated during 6-day test period. To avoid the carryover 
effect stimulation was discontinued for 24 hours between consecutive test 
periods. On the last 3 days of each test period a voiding diary and 
questionnaire were completed. Changes in the clinical response and pain 
symptoms were compared between the 4 pulse rates using multivariate 
analysis. 
 
Results: Of the 50 patients included in the study 40 (80%) were female. 
Mean ± SD age was 55.5 ± 12.3 years. Of the patients 41 (82%) had 
overactive bladder symptoms and 9 (18%) were in chronic nonobstructive 
urinary retention. No significant difference was found in  clinical outcome on 
the voiding diary and questionnaire between the pulse rates and none of the 
4 rates was significantly related to sacral neuromodulation associated pain. 
However, individuals appeared to benefit from changing the pulse rate in 
terms of treatment efficacy and stimulation related pain. 
 
Conclusions: On the group level none of the 4 pulse rates appeared to have 
a significantly different effect on clinical outcome or sacral neuromodulation 
related pain. However, a individualized approach to optimize treatment 
efficacy by changing the pulse rate appears to be useful.  
The Effect of Pulse Rates Changes on Clinical Outcome in Sacral Neuromodulation 
 
 37 
Introduction 
Patients with refractory OAB symptoms, with or without urgency 
incontinence and nonobstructive urinary retention who do not respond to 
conservative treatment, such as pharmacotherapy or pelvic floor training, 
can achieve symptom relief by SNM therapy [1-4]. The implantable 
neurostimulator can have various settings. The waveform that the 
stimulator produces is a square wave pulse. The pulse rate can be set 
between 2.1 and 130 Hz, pulse width can be set between 60 and 450 
µseconds, and amplitude can be changed from 0.05 to 10.55V.   
At most centers where patients with SNM are treated a pulse rate between 
10 and 16 Hz is commonly used [5-7]. This choice is based on the optimal 
setting by measuring urethral closure pressure [8]. Data from animal studies 
suggest that the pulse rate should not exceed 50 Hz since this might be 
detrimental to the stimulated nerve due to early axonal degeneration [9, 
10]. Currently patients with apparently opposite dysfunctions of the lower 
urinary tract (OAB vs. urinary retention) are treated using the same 
stimulation parameters because to our knowledge no available studies have 
clearly evaluated the clinical response to different stimulation parameters.  
A parameter that may have an influence is the pulse rate. We evaluated the 
impact of pulse rate changes during SNM on the clinical outcome. We also 
evaluated the effect of changing the pulse rate on sensory responses and 
SNM related pain symptoms. 
 
Methods 
This pilot study included patients with a suboptimal effect of SNM treatment 
using the standard parameter settings. Ethical approval for the study was 
granted and all patients provided written informed consent before the study 
started. Patients with urgency urinary incontinence and those with chronic 
non-obstructive urinary retention were recruited during followup at our 
outpatient clinic. All patients had an implantable pulse generator and had 
received SNM therapy for at least 6 months based on a good response 
during test stimulation, defined as more than 50% improvement in key 
voiding diary variables compared to baseline.  
A suboptimal effect was defined in patients with incontinence as the 
persistence of some degree of incontinence and in patients with retention as 
the need for catheterization to evacuate post-void residual urine. Only 
patients with a suboptimal effect were included in  analysis, accepting the 
hypothesis that no symptom improvement can be expected in those  who 
already experience a full clinical response (patients with no more 
symptoms). Patients who experienced decreased treatment efficacy since 
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implantation were evaluated for technical malfunction or lead migration. 
Restoration of treatment efficacy was attempted by changing the polarity. 
Initial baseline settings were amplitude just above the sensory threshold, 
frequency 10 Hz and a pulse width 210 µseconds. Patients were asked to 
maintain a voiding diary for 3 days, and complete a questionnaire. During 
the experimental protocol 4 pulse rates were used, each for a 6-day 
stimulation period. To avoid the carryover effect stimulation was 
discontinued for 24 hours between the different test periods. For each test 
period patients were asked to complete a voiding diary on days 4 to 6 of the 
period and answer the questionnaire on day 6. Pulse rates tested during the 
experimental protocol were  5.2, 10 (control setting), 21 and 40 Hz. The 
sequence was determined by randomization and blinded for each patient. 
Pulse width was not changed during the whole protocol (210 µseconds) and 
patients controlled the amplitude to just above sensory threshold.  
The primary outcome was the change in voiding diary parameters among 
the 4 settings (5.2 vs. 10 vs. 21 vs. 40 Hz). In patients with urinary 
incontinence the parameters were the number of voids daily, voided volume 
per void, daily incontinence episodes and daily pad use. In patients with 
urinary retention the parameters were the number of catheterizations daily, 
catheterized volume per catheterization, voided volume per void and the 
number of voids daily. A change of 20% or more in the relevant voiding diary 
parameters compared to baseline was considered clinically significant.  
Secondary outcomes were derived from the questionnaire. Part 1 consisted 
of questions on  stimulation related pain symptoms. At each pulse rate the 
site of the sensory response and the occurrence of pain or discomfort were 
documented. Part 2 consisted of 7 questions to evaluate subjective voiding 
symptoms using a visual analogue score of 0-worst to 100-best.  
 
Statistical analysis 
Since this pilot study was 1 of the first to analyze the effect of the 4 pulse 
rate settings on the response of patients of SNM therapy, it was difficult to 
perform power analysis without knowing in advance the strength of the 
associations of the predictors used. Thus, we used a tentative initial number 
of 50 patients to gauge the sensibility of test settings. The paired t tests was 
used to compare baseline (control) and 10 Hz outcomes to assess the 
validity of diary results. Repeated measures ANOVA was done to test the 
results between the 4 pulse rates. The effects of the patient age and 
complaint type (OAB and nonobstructive urinary retention) subgroups on 
pulse rate settings were analyzed. If age had a statistically significant effect, 
optimal dichotomous categorizing was done to determine age cutoffs. 
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Statistical significance was considered at p<0.05. For all data analyses SPSS 
PC, version 16.0 were used.    
 
Results 
Clinical outcome 
Of the 50 patients  40 were female (80%). Mean ± SD age was 55.5 ± 12 
years. A total of 41 patients (82%) had urinary incontinence and 9 (18%) had 
urinary retention. Mean followup after implantation was 6.2 ± SD 4.8 years. 
Comparison of the baseline 10 Hz voiding diary with showed no  statistically 
significant differences in any outcome parameter (see table).  
Of the patients 38 (76%) experienced clinical improvement, defined as a 
greater than 20% change in voiding diary parameters, for at least 1 of the 4 
pulse rate settings. Part A of the figure shows the number of patients with 
clinical improvement for each pulse rate. Eight of the 41 patients (20%) with 
OAB were completely dry with at least one setting, and 2 of the 9 (22%) 
patients with retention had no more need for catheterization. 
When comparing the effect of the 4 pulse rates, no significant relation was 
found between any rate and a change in voiding diary parameters on 
univariate analysis. Multivariate analysis of the voiding diary data, controlled 
for age and type of complaint, revealed a significant difference in the 
number of voids daily at the 40 Hz setting (p=0.036), but only in younger 
patients. For rates other than 40 Hz this effect was not found. No statistically 
significant difference was noted in the other voiding diary parameters (see 
table).  
Multivariate analysis of questionnaire parameters also revealed a significant 
difference in the number of voids daily (p=0.021) in younger patients only. 
At rates other than 40 Hz this effect was not noted. No statistically 
significant difference was found for the other visual analogue scale 
parameters (see table). Optimal dichotomous categorizing of age resulted in 
a cutoff of 44 years.   
 
Sensory response 
During pulse rates reprogramming patients were repeatedly asked to locate 
the sensation site. Answers were categorized as the: 1) anal area, 2) perineal 
or genital area, 3) buttock area or 4) another area. Of the 50 patients 38 
(76%) reported a change in the sensation site for at least 1 of the 4 pulse 
rates. Patients reported different sensation sites at different pulse rates, but 
we noted no significant relation between any 1 rate and the sensation site. 
Furthermore, no relation was found between the sensation site and clinical 
effect.  
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A, effect of each pulse rate setting on clinical outcome on voiding diary in 50 patients. Improvement was 
defined as greater than 20% improvement. B, of 28 patients those with no stimulation related pain at 
baseline who had onset of pain during study. C, of 22 patients those with perceived stimulation related 
pain at baseline who had decreased pain during study. 
Pain symptoms 
During the study we documented perceived pain symptoms related to 
stimulation at different pulse rates. At baseline 28 patients reported no pain 
or discomfort related to electrical stimulation. Of these patients 12 (43%) 
reported de novo pain during the study at 1 pulse rate setting but only 5 
(18%) reported that the pain was bothersome in daily life. Part B of the 
figure shows the number of patients with onset of pain symptoms at each 
pulse rate. Statistical analysis revealed no significant relation between any of 
the 4 pulse rates and pain symptoms. 
Of the 50 patients 27 reported stimulation related pain at baseline, including 
4 in whom the pain was bothersome in daily life. Of the 22 patients 18 (82%) 
reported a decrease in pain symptoms for at least 1 pulse rate setting during 
the study. Part C of the figure shows the number of patients with decreased 
pain symptoms at each pulse rate. No significant relation was found for any 
of the 4 settings and decreased pain symptoms. There was no relation 
between the disappearance of pain at a certain pulse rate and clinical 
efficacy. 
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Diary and visual analogue scale questionnaire results in 50 patients  
 
 
 
 
Mean ± 
SD 
Baseline 
Mean ± 
SD 5.2 
Hz 
Mean 
± SD 10 
Hz 
Mean 
± SD 21 
Hz 
Mean 
± SD 40 
Hz 
p Value 
Base vs 10 
Hz (paired 
sample t 
test) 
Univariate 
(repeated 
measures 
ANOVA) 
Diary 
Overall:        
Max voided vol (ml) 418 ± 149 426 ± 
154 
428 ± 
149 
410 ± 
134 
411 ± 
136 
0.603 0.323 
No. voids/day† 8.3 ± 3.2 8.2 ± 
2.8 
8.3 ± 
2.8 
8.0 ± 
2.8 
8.0 ± 
2.6 
0.734 0.610 
Voided vol/void (ml) 225 ± 83 225 ± 
77 
230 ± 
78 
224 ± 
81 
228 ± 
82 
0.715 0.566 
OAB wet (41 pts):        
Incomplete 
episodes/day 
4.4 ± 2.4 3.6 ± 
2.8 
3.5 ± 
3.0 
3.7 ± 
2.9 
3.9 ± 
2.9 
0.080 0.862 
Pads/day 2.5 ± 1.9 2.3 ± 
2.2 
2.1 ± 
1.6 
2.1 ± 
1.6 
1.8 ± 
1.5 
0.188 0.525 
Severe leakage 1.5 ± 0.5 1.3 ± 
0.5 
1.4 ± 
0.6 
1.2 ± 
0.6 
1.4 ± 
0.5 
0.058 0.641 
Retention (9 pts):        
Max 
vol/catheterization 
(ml) 
233 ± 157 149 ± 
145 
140 ± 
128 
171 ± 
94 
161 ± 
164 
0.734 0.724 
No. 
catheterizations/day 
6.5 ± 2.9 4.4 ± 
4.1 
5.0 ± 
3.5 
5.6 ± 
3.5 
4.1 ± 
3.5 
0.278 0.407 
Catheterized 
vol/catheterization 
(ml) 
126 ± 104 88 ± 97 88 ± 85 113 ± 
75 
90 ± 
105 
0.315 0.606 
Questionnaire 
General urinary 
voiding 
57 ± 25 57 ± 23 59 ± 25 57 ± 24 59 ± 26 0.716 0.882 
No. voids† 54 ± 24 57 ± 25 51 ± 28 56 ± 25 58 ± 28 0.329 0.331 
Urinary flow 52 ± 32 51 ± 29 47 ± 29 48 ± 32 52 ± 29 0.543 0.463 
Urinary urge sensation 55 ± 31 56 ± 28 55 ± 30 53 ± 30 56 ± 30 0.808 0.781 
Empty bladder 
sensation 
51 ± 33 58 ± 32 55 ± 33 57 ± 34 57 ± 34 0.255 0.686 
Bladder control 49 ± 30 57 ± 28 56 ± 30 55 ± 28 59 ± 28 0.192 0.824 
Dry 55 ± 32 62 ± 31 59 ± 30 61 ± 28 61 ± 27 0.369 0.798 
 Four-way analysis of 5.2 vs 10 Hz vs 21 Hz vs 40 Hz. 
†
 Multivariate risk factor was age or complaint type and 
final model included difference in number of voids at 40 Hz vs remainder by age 44 or less and greater than 44 
years (diary and questionnaire best fit repeated ANOVA/ANCOVA p = 0.004 and 0.012, respectively). 
Chapter 3 
 
 42 
Discussion  
SNM is a well accepted treatment option in cases of OAB or nonobstructive 
urinary retention that are refractory to conservative treatment. At most 
clinics where SNM is applied it is customary to set the pulse rate of the 
implantable neurostimulator between 10 and 16 Hz [5-7]. However, these 
settings are based on early SNM experiments, in which optimal stimulation 
parameters were determined by the effect on urethral closure pressure [8]. 
Today it is generally assumed that the SNM mechanism of action involves 
the modulation of spinal cord reflexes and brain networks by peripheral 
afferents rather than direct stimulation of the motor response of the 
detrusor or urethral sphincter [11].  
In electrophysiological experiments on rat dorsal root ganglion neurons the 
pulse rate by natural physiological stimuli was approximately 5 Hz in C, 15 Hz 
in Aδ and 100Hz in Aβ fibres [12, 13]. Thus pulse rate alterations could have 
different effects on different fiber types and SNM treatment efficacy may be 
optimized by evaluating the clinical effect of different pulse rates. 
In a study by Tai et al of pudendal nerve stimulation 3 and 20Hz pulse rates 
in chronic spinal cord injured rats different effects were observed on bladder 
capacity and voiding efficiency [14]. 
To date few clinical studies have been done to evaluate the effect of 
different pulse rates in patient who receive SNM. In 2003 Malaguti et al used 
somatosensory evoked potentials of the pudendal nerve to evaluate the 
suprasacral action of SNM [15]. Measurements were made at 21 and 40 Hz. 
They found a higher decrease in pudendal somatosensory evoked potentials 
latency when the pulse rate was set to 40 Hz, indicating that a 40 Hz setting 
more effectively facilitates afferent transmission to the central nervous 
system.  
In patients with faecal incontinence Dudding et al noted that a 31 Hz pulse 
rate resulted in a significant increase in rectal compliance compared to that 
at 14 Hz [16]. Although these findings indicate that pulse rate alterations can 
influence nerve transmission or rectal compliance, to our knowledge the 
effect of pulse rate alterations on the clinical outcome has never been 
evaluated in a large group of patients. 
In our study population no specific pulse rate appeared to be superior in 
terms of the  clinical effect. Younger age has already been implicated as a 
positive predictive factor for clinical success [17-20]. In our study the 40 Hz 
setting resulted in a significantly lower number of voids daily in younger 
patients. However, in our opinion, the clinical relevance of this finding seems 
limited. 
Although no significant difference was found among the pulse rates, our 
results clearly show that pulse rate alterations can improve the clinical 
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response in individuals since 76% experienced improved voiding symptoms 
for at least 1 pulse rate setting. Also, 20% of patients with OAB became 
completely dry and 22% with retention had no more need for 
catheterization. This means that changing the pulse rate can be useful to 
improve treatment efficacy in patients who experience suboptimal SNM 
effect.  
Generally sensation sites are used as a guide for proper stimulation during 
screening or reprogramming visits in patient receiving SNM. It has been 
assumed that the optimal sensory response is located in the anal or genital 
area since this is the most commonly observed response during stimulation 
of the S3 nerve root [21]. However, there is not much evidence in the 
literature for this assumption, and no studies have clearly evaluated the 
relation between the sensation site and clinical effect. In our series most 
patients noticed a change in sensation site for at least 1 pulse rate setting. In 
some patients the sensation site changed from a desired area, such as the 
anus, to an undesired area such as the buttock. We found no significant 
relation between pulse rate and sensation site or between sensation site 
and clinical effect. Hence, these data question the role of sensation site as 
predictive factor for optimal stimulation. 
 
To our knowledge the effect of pulse rate settings on stimulation related 
pain symptoms has never been evaluated, although it is believed that higher 
stimulation frequencies may result in painful stimulation. A pulse rate higher 
than 50Hz is not recommended due to the possibility of nerve injury and, 
thus, it is advised to set the pulse rate at 10 to 16 Hz [10, 22]. We evaluated 
the effect on pain symptoms of 4 pulse rates and none was significantly 
related to the onset of stimulation related pain. Although pain could be 
decreased by changing the pulse rate in individuals with pain symptoms at 
baseline, no relation was found between a specific pulse rate and a decrease 
in pain.  
 
These findings imply that all 4 pulse rates can be effectively used during 
reprogramming of the neurostimulator and there does not seem to be a 
preference for 1 particular setting. However, since the number of patients in 
this pilot study was relatively small, power may have been too low to detect 
a significant difference between the pulse rates. Furthermore, we only 
evaluated the effect of each pulse rate during 1 week. Thus, the effect of 
chronic stimulation cannot be predicted. It would be interesting to evaluate 
the effect of different pulse rates in a group of patients directly after 
implantation. Also, we studied patients who were treated with SNM for 
many years, which may have influenced our results. Unfortunately we did 
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not evaluate the effect of turning the stimulator off in these patients before 
the start of the trial. Finally, we did not include a control group and, thus, 
the role of a possible placebo effect cannot be evaluated. 
 
Conclusion 
In this pilot study none of the 4 pulse rates appears to have had a 
significantly different effect on clinical outcome or stimulation related pain. 
Nevertheless, an individualized a approach to optimize treatment efficacy by 
changing the pulse appears to be useful.  
 
References 
1. Aboseif S, Tamaddon K, Chalfin S, Freedman S, Kaptein J: Sacral 
neuromodulation as an effective treatment for refractory pelvic floor 
dysfunction. Urology 2002, 60(1):52-56. 
2. Aboseif S, Tamaddon K, Chalfin S, Freedman S, Mourad MS, Chang JH, 
Kaptein JS: Sacral neuromodulation in functional urinary retention: an 
effective way to restore voiding. BJU international 2002, 90(7):662-665. 
3. Abrams P AK, Birder L, Brubaker L et al. : Recommendations of the 
International Scientific Committee: Evaluation and treatment of urinary 
incontinence, pelvic organ prolapse and faecal incontinence. In: 
Incontinence. edn. Edited by Abrams P CL, Khoury S, Wein A. Plymouth, 
England: Health Publication Ltd; 2009: 1767-1816. 
4. van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP, Lycklama a Nijholt 
AA, Siegel S, Jonas U, Fowler CJ, Fall M, Gajewski JB, Hassouna MM et al: 
Results of sacral neuromodulation therapy for urinary voiding dysfunction: 
outcomes of a prospective, worldwide clinical study. J Urol 2007, 
178(5):2029-2034. 
5. Schmidt RA, Jonas U, Oleson KA, Janknegt RA, Hassouna MM, Siegel SW, 
van Kerrebroeck PE: Sacral nerve stimulation for treatment of refractory 
urinary urge incontinence. Sacral Nerve Stimulation Study Group. J Urol 
1999, 162(2):352-357. 
6. Jonas U, Fowler CJ, Chancellor MB, Elhilali MM, Fall M, Gajewski JB, 
Grunewald V, Hassouna MM, Hombergh U, Janknegt R et al: Efficacy of 
sacral nerve stimulation for urinary retention: results 18 months after 
implantation. J Urol 2001, 165(1):15-19. 
7. Hassouna MM, Siegel SW, Nyeholt AA, Elhilali MM, van Kerrebroeck PE, Das 
AK, Gajewski JB, Janknegt RA, Rivas DA, Dijkema H et al: Sacral 
neuromodulation in the treatment of urgency-frequency symptoms: a 
multicenter study on efficacy and safety. J Urol 2000, 163(6):1849-1854. 
8. Thon WF, Baskin LS, Jonas U, Tanagho EA, Schmidt RA: Neuromodulation of 
voiding dysfunction and pelvic pain. World J Urol 1991, 9:138-141. 
9. Hohenfellner M, Schultz Lampel D, Dahms S, Matzel K, Thuroff JW: Bilateral 
chronic sacral neuromodulation for treatment of lower urinary tract 
dysfunction. Journal of urology 1998, 160(3 Pt 1):821-824. 
The Effect of Pulse Rates Changes on Clinical Outcome in Sacral Neuromodulation 
 
 45 
10. Agnew WF, McCreery DB, Yuen TG, Bullara LA: Histologic and physiologic 
evaluation of electrically stimulated peripheral nerve: considerations for 
the selection of parameters. Annals of biomedical engineering 1989, 
17(1):39-60. 
11. Kessler TM, Fowler CJ: Sacral neuromodulation for urinary retention. 
Nature clinical practice 2008, 5(12):657-666. 
12. Handwerker HO, Anton F, Reeh PW: Discharge patterns of afferent 
cutaneous nerve fibers from the rat's tail during prolonged noxious 
mechanical stimulation. Experimental brain research Experimentelle 
Hirnforschung 1987, 65(3):493-504. 
13. Koga K, Furue H, Rashid MH, Takaki A, Katafuchi T, Yoshimura M: Selective 
activation of primary afferent fibers evaluated by sine-wave electrical 
stimulation. Molecular pain 2005, 1:13. 
14. Tai C, Wang J, Wang X, de Groat WC, Roppolo JR: Bladder inhibition or 
voiding induced by pudendal nerve stimulation in chronic spinal cord 
injured cats. Neurourology and urodynamics 2007, 26(4):570-577. 
15. Malaguti S, Spinelli M, Giardiello G, Lazzeri M, Van Den Hombergh U: 
Neurophysiological evidence may predict the outcome of sacral 
neuromodulation. Journal of urology 2003, 170(6 Pt 1):2323-2326. 
16. Dudding TC, Vaizey CJ, Gibbs A, Kamm MA: Improving the efficacy of sacral 
nerve stimulation for faecal incontinence by alteration of stimulation 
parameters. The British journal of surgery 2009, 96(7):778-784. 
17. Govaert B, Melenhorst J, Nieman FH, Bols EM, van Gemert WG, Baeten CG: 
Factors associated with percutaneous nerve evaluation and permanent 
sacral nerve modulation outcome in patients with fecal incontinence. 
Diseases of the colon and rectum 2009, 52(10):1688-1694. 
18. Gourcerol G, Gallas S, Michot F, Denis P, Leroi AM: Sacral nerve stimulation 
in fecal incontinence: are there factors associated with success? Diseases of 
the colon and rectum 2007, 50(1):3-12. 
19. Amundsen CL, Romero AA, Jamison MG, Webster GD: Sacral 
neuromodulation for intractable urge incontinence: are there factors 
associated with cure? Urology 2005, 66(4):746-750. 
20. Amundsen CL, Webster GD: Sacral neuromodulation in an older, urge-
incontinent population. American journal of obstetrics and gynecology 
2002, 187(6):1462-1465; discussion 1465. 
21. Schmidt RA, Senn E, Tanagho EA: Functional evaluation of sacral nerve root 
integrity. Report of a technique. Urology 1990, 35(5):388-392. 
22. Agnew WF, McCreery DB: Considerations for safety with chronically 
implanted nerve electrodes. Epilepsia 1990, 31 Suppl 2:S27-32. 
 
 
 
 
 
 
Chapter 3 
 
 46 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Chapter 4  
 
 
 
Long-term Results of Sacral 
Neuromodulation with the Tined Lead 
Procedure 
 
Tom A.T. Marcelissen, Randall K. Leong, Rob A. de Bie, Philip 
E.V. van Kerrebroeck, Stefan G.G. de Wachter
 
Journal of Urology 2010; 184 (5):1997
47 
 
-2000 
Chapter 4 
 
 
 48 
Abstract 
Purpose: We present long-term followup data on the outcome of sacral 
neuromodulation using the tined lead procedure.  
 
Materials and Methods:  We conducted a single center study including all 
patients who received an implantable neurostimulator between 2002 and 
2005 using the tined lead technique. Treatment efficacy was evaluated by 
comparing the data of a 3-day voiding diary filled out in May 2009 to the 
data before the onset of sacral neuromodulation treatment (baseline). 
Clinical success was defined as more than 50% improvement in at least 1 of 
the relevant voiding diary parameters. 
 
Results: A total of 64 patients underwent implantation with an implantable 
neurostimulator using the tined lead procedure. Mean followup was 53 
months (range 35 to 77). Five patients died of causes unrelated to sacral 
neuromodulation and they were not included in analysis. The implantable 
neurostimulator was removed from 7 patients and 3 stopped using the 
neurostimulator. Voiding diary analysis showed that 38 of 59 patients (64%) 
were successfully treated. There were 21 patients (33%) who underwent a 
surgical revision due to an adverse event and 1 (1.6%) who underwent lead 
revision because of suspected lead migration. 
 
Conclusions: Sacral neuromodulation with the tined lead procedure is a safe 
and effective treatment for patients with overactive bladder symptoms or 
urinary retention. 
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Introduction 
Sacral neuromodulation (SNM) is an accepted treatment option for patients 
with idiopathic overactive bladder syndrome (OAB) or chronic non-
obstructive urinary retention that is refractory to conservative treatment [1-
3]. Since Food and Drug Administration approval in 1997, an increasing 
number of patients have been treated with SNM. Initially the permanent 
lead was implanted using an open surgical technique with an incision made 
in the midline over the sacrum and the lead placed under direct vision into 
the sacral foramen. The lead was then secured with a suture to the sacral 
periosteum. The long-term success rate for this initial procedure is reported 
to be 60-70% [4-6].  
In 2002 a new technique was introduced that enabled percutaneous 
placement of a self-anchoring, tined silicone lead [7, 8]. This lead can be 
easily placed in the third sacral foramen under radiological guidance. 
Potential advantages of the tined lead procedure (TLP) include a shorter 
operation time, reduced risk of infection, less pain and shorter postoperative 
recovery time. In addition, the lead can be inserted with the patient under 
local anesthesia, enabling evaluation of the sensory responses to acute 
stimulation.  
Short-term studies showed a decrease in the numbers of adverse events and 
the occurrence of lead migration with the TLP [9, 10]. However, the efficacy 
and number of adverse events in the long-term are currently unevaluated. 
The primary objective of this study was to assess the long-term efficacy and 
adverse events of SNM with the tined lead procedure. A Secondary objective 
was to correlate the degree of improvement during test stimulation with 
long-term outcome. 
 
Methods 
This single center observational study included all patients who were 
screened for SNM therapy between 2002 and 2005. The study was approved 
by the ethical committee and all participants signed an informed consent. 
Patients included those with idiopathic OAB symptoms, with (OAB wet) or 
without (OAB dry) incontinence, and those with chronic nonobstructive 
urinary retention. All cases were refractory to conservative treatments or 
could not tolerate the side effects. All patients in the retention group 
performed clean intermittent catheterization and had more than 100 ml 
residual volume. No patients had signs of anatomical obstruction. 
Patients received an implantable neurostimulator (INS) after showing a 
successful response to PNE or first stage tined lead screening tests. Success 
was defined as more than 50% improvement in at least one of the relevant 
voiding diary parameters compared to baseline. For OAB wet cases these 
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parameters included a reduction in daily episodes of incontinence or pad 
use, and for OAB dry cases a reduction in the number of daily voids or an 
increase in voided volume per void. For patients with non-obstructive 
urinary retention parameters were a reduction in the number of daily 
catheterizations or increase in voided volume. 
Between 2002 and 2005 all patients were initially screened with a PNE test 
unless they were at high risk for lead migration (for instance, those who 
were obese or underweight). Patients who showed a negative response to 
PNE were additionally screened with the TLP. The tined lead placement was 
performed as previously described [7, 8]. The lead (InterStim Model 3889) 
was placed in the left or right S3 foramen with fluoroscopy guidance. All 
procedures were performed under local anesthesia in an outpatient setting.   
After implantation, patients visited the outpatient clinic after 6 weeks, 6 
months and yearly thereafter. In cases of decreased efficacy the impedances 
and battery life span were checked. Parameter settings were adjusted to 
restore efficacy. In case of permanent loss of efficacy electrode position and 
cable integrity were checked using fluoroscopy. Adverse events and 
reoperations were reported for all implanted cases. 
In May 2009 all patients who were still using the INS were asked to keep a 
voiding diary to record the effect of SNM on urinary symptoms. SNM 
therapy was considered successful if 50% or more improvement was noted 
compared to baseline in any of the primary voiding diary variables. The 
variables at baseline and followup were compared using the Wilcoxon 
signed rank test. Treatment in those who had the system explanted or 
discontinued SNM therapy was considered unsuccessful and the patients 
were assumed to return to baseline symptoms.  
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Overview of all patients screened for SNM treatment. Note that 16 patients were 
immediately screened with TLP without prior PNE test due to increased risk of lead migration. 
Total of 64 patients showed positive response to screening and received INS.
Results 
Screening and followup 
Between 2002 and 2005, 92 patients were screened for SNM, of whom 64 
(70%) responded successfully and received an INS using the tined lead 
procedure. Of the 64 patients, 53 were female and 11 were male with a 
mean age of 49 years (range 22 to 75, SD 12). (see figure 1 and table 1). 
During follow-up 5 patients died of causes unrelated to neuromodulation. 
These patients were not included in the evaluation of treatment efficacy 
since no objective data could be obtained. Of the remaining 59 
had overactive bladder syndrome (40 OAB wet and 5 OAB dry) and 14 had 
non-obstructive urinary retention.  
 
By May 2009 of 59 patients 49 were still using their INS. There were 7 
patients who had the INS explanted, including 1 due to psychiatric
due to repeated need for magnetic resonance imaging evaluation, 3 due to 
loss of efficacy (1 after a vaginal wall correction and 2 after minor trauma) 
and 2 patients because of persistent stimulation related pain. Three patients 
turned their INS off permanently, including 2 due to loss of efficacy and 1 
after trauma requiring a suprapubic catheter due to reduced mobility. These 
patients preferred not to undergo INS removal. 
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Table 1. Overview of long-term results    
 OAB 
Wet 
OAB 
Dry 
Retention Totals 
(%) 
No. died 3 1 1 5 (8) 
No. explant/stimulator off 6 0 4 10 (16) 
No. less than 50% improvement in voiding diary 9 1 1 11 (17) 
No. greater than 50% improvement in voiding 
diary 
25 4 9 38 (59) 
Totals (%) 43 (67) 6 (9) 15 (24) 64 (100) 
 
Voiding diary analysis 
The voiding diary was filled out by 49 patients. Patients who had the device 
explanted or turned the INS off were assumed to return to baseline 
symptoms. Mean follow-up was 51 months (range 35 to 74, SD 11). The 
changes in voiding diary parameters for each subgroup are illustrated in 
table 2.  
 
A sub-analysis was performed for patients with 50 to 90% and more than 
90% improvement in voiding diary data during test stimulation. The long-
term success rate for each group was 52% and 80% respectively. A 
borderline significant association was found between patients with greater 
than 90% improvement during test stimulation and long-term success 
(Fisher's exact test p= 0.05, OR 3.6, 95% CI 1.1-11.7).  
 
Safety and complications 
Adverse events and reoperations were evaluated for all 64 patients. No 
serious or life-threatening adverse events occurred. In 3 patients a 
haematoma was seen perioperatively which was treated with antibiotics. A 
wound infection developed in 1 patient which required INS removal. 
Postoperatively 23 reoperations were performed in 21 patients (33% 
reoperation rate). In 7 patients the INS was removed, in another 7 the INS 
was repositioned for pain at the INS site and in 5 a lead revision was 
required (1 due to lead migration, 3 due to decreased efficacy and 1 due to 
pain). In 4 patients the INS had to be replaced because of battery depletion. 
Mean followup before battery replacement was 62.3 months (range 49 to 
75).  
 
There were 17 patients (27%) who reported pain during follow-up. Pain at 
the INS site was reported most commonly, followed by pain caused by 
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bothersome stimulation. Of these patients 9 were treated by changing the 
stimulation parameters. The remaining 8 patients required surgical 
intervention, because reprogramming the INS was insufficient. 
 
Readjustment of stimulation parameters was evaluated for each patient 
since implantation. The mean number of reprogramming sessions was 2.8 
per patient (0.7 per year), and the most common reasons were loss of 
efficacy and painful stimulation. There were 11 patients (17%) who not 
require any readjustment of the parameters, 41 patients (66%) required up 
to 5 reprogramming visits and 12 (17%) required more than 5 
reprogramming visits. Of these 12 patients, none was successfully treated 
with mere adjustment of the stimulation parameters.  
 
Table 2. Results of voiding diary analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
            p <0.01, 
†
 p <0.05 
 
Discussion 
With the introduction of the TLP, sacral neuromodulation has become a 
minimally invasive treatment for patients with overactive bladder syndrome 
or urinary retention. Although some advantages of this new technique have 
been demonstrated in short-term trials, the efficacy of treatment and the 
sufficiency of lead fixation in the long-term are unclear.  
 Mean Baseline 
(SD) 
Mean Test Stimulation 
(SD) 
Mean Followup 
(SD) 
OAB wet: 
Voided vol 
(ml)/void 
151 (70) 228 (68) 183 (72)† 
Voids/day 11.2 (6.1) 7.7 (3.3)† 9.2 (3.6) 
Leakage/day 7.7 (5.0) 2.1 (2.1) 4.0 (3.8) 
Pads/day 4.6 (3.0) 0.7 (0.8) 2.3 (2.8) 
OAB dry: 
Voided vol 
(ml)/void 
131 (17) 231 (28)† 195 (35)† 
Voids/day 16.5 (2.3) 7.0 (1.4)† 9.1 (3.2)† 
Leakage/day 0.0 (0.0) 0 (0.0) 0.0 (0.0) 
Retention: 
Voided vol 
(ml)/void 
96 (101) 267 (109) 203 (126) 
Voids/day 4.2 (3.5) 6.8 (2.3)† 5.9 (2.8)† 
Catheters/day 4.7 (2.0) 4.5 (2.1) 1.9 (2.8) 
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In our study, the success rate was 64% (38 of 59 implanted cases), which is 
comparable to that of previous long-term studies evaluating the nontined 
lead [4-6]. This suggests that the minimally invasive nature of the TLP does 
not decrease treatment efficacy. However, it does permit adequate 
placement of the lead to be performed with the patient under local 
anesthesia using guidance with fluoroscopy, and clinical sensory and motor 
responses. 
Patients who showed a large improvement during screening (greater than 
90% improvement in voiding diary parameters) tended to do better in the 
long term than patients who showed between 50 and 90% improvement (p= 
0.05). This finding suggests that the clinical response during the test phase 
has some predictive value for treatment efficacy in the long term and 
reinforces the importance of good patient selection.   
 
The number of adverse events appears to decrease with the TLP compared 
to the non tined lead, since in the current study electrode migration was 
seen in only 1 patient (1.6%). Long-term studies conducted before the 
introduction of the tined lead showed electrode migration rates between 
6.7% and 27% [4-6, 11]. The low rate of electrode migration in our study 
could be a result of better electrode fixation with the new tined lead 
technique, and similar results were previously shown in short-term studies 
with the TLP [10, 12, 13].  
The number of patients requiring surgery due to an adverse event was 33%, 
which is only slightly lower than reported revision rates using the nontined 
lead, which range from 38% to 40% [4-6]. Comparison among various studies 
may be difficult due to differences in patient selection and surgical 
procedures. Furthermore, replacement of the INS due to battery depletion 
was included in the number of adverse events in our study. A long-term 
study conducted in our centre using the nontined lead procedure showed a 
revision rate of 48% [11]. Therefore, the new tined lead technique seems to 
result in a lower revision rate, mostly due to a decrease in the number of 
infections and lead migrations. 
In 1999 the location of INS placement was changed from the lower abdomen 
to the buttock, which facilitated the surgical procedure and was thought to 
reduce device related pain[14]. In our study each INS was placed in the 
buttock but still the operation rate for repositioning the INS due to pain 
(11%) was similar to the rate reported in a worldwide long-term study using 
the initial technique (12%) [4]. Therefore, it is questionable whether buttock 
placement actually decreases device related pain. 
Since to our knowledge no true algorithm exists for the adjustment of the 
stimulation parameters, the number of reprogramming visits in our study 
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varied per patient. Most patients (82%) required 1 or more reprogramming 
sessions. In all patients who had more than 5 reprogramming visits 
parameter adjustment failed to resolve the adverse event. Therefore, we 
believe performing more than 5 reprogramming visits for the same adverse 
event seems ineffective. 
  
Conclusion 
Long-term sacral neuromodulation with the tined lead is a safe and effective 
treatment for patients with overactive bladder symptoms or urinary 
retention. Using the tined lead appears to reduce the occurrence of lead 
migration but does not increase the long-term success rate compared to 
previous reports using the nontined lead. Patients who show more than 90% 
improvement during test stimulation appear to have a higher chance of 
long-term success than patients with 50 to 90% improvement. 
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Abstract  
Purpose: We systematically assessed a long-term satisfaction and patient 
experience with sacral nerve modulation therapy. 
 
Materials and Methods: All patients who received sacral neuromodulation 
therapy between 1990 and 2007 at our centre and who are still had the implant 
were included in the survey. All received a postal questionnaire regarding their 
satisfaction and their experiences with the system, such as side effects, 
complications, burden, impact on sexuality and defecation changes.  
 
Results: Of the 275 questionnaires sent 207 were returned for a 75% response 
rate. The population was 83% female. Overall treatment was done for 
overactive bladder syndrome, nonobstructive urinary retention, combined 
overactive bladder and retention, and pelvic pain in 55%, 24%, 20% and 1% of 
patients, respectively. Overall satisfaction with sacral neuromodulation was 
high at 90%. No correlations were found between the satisfaction rate, and 
pretreatment age, gender, complaint type, sexual dysfunction or therapy 
duration. However, 56% of patients reported side effects, such as pain at the 
internal nerve stimulator site and due to stimulation. However, 89% of these 
patients did not seek further therapy. Of patients with additional defecation 
problems 47% experienced relief of complaints. 
 
Conclusions: This study shows a high satisfaction rate in patients with SNM. 
There was no relation between patient age, complaint type, therapy duration 
or side effects and the satisfaction rate. The number of side effects was limited 
but further analyses in prospective cohorts should identify patients who are 
likely to have side effects or stop SNM  treatment. 
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Introduction 
For almost 2 decades sacral neuromodulation (SNM) therapy has been used as 
a safe, effective treatment option in patients with lower urinary tract 
dysfunction. Clinical studies show its positive effect for refractory urge 
incontinence, nonobstructive urinary retention and urgency-frequency 
syndrome [1-4]. In addition to urological disorders, SNM is also being done for 
fecal incontinence and chronic constipation [5, 6].  
Currently, most studies of SNM have focused on clinical efficacy or technique 
improvement. The outcome parameters mainly used are clinically oriented such 
as greater than 50% improvement in 1 or 2 relevant urinary symptoms and the 
presence of adverse events. Impact on quality of life has been described but to 
a lesser extent and as mostly evaluated by non-Overactive Bladder syndrome 
(OAB) or retention specific questionnaires [2, 4, 7]. Since functional bladder 
disorders have a negative impact on quality of life, evaluating patient 
satisfaction is also important because it may provide an overall view of how the 
patients experience treatment on a daily basis. Our main goal was to 
systematically evaluate long-term satisfaction in patients on SNM and evaluate 
their daily experiences with the treatment.  
 
Materials and Methods 
A postal questionnaire was sent to all patients at our center who had been 
treated with SNM for at least 1 year. Implantation was done from 1990 to 2007. 
They were asked to reply within 14 days and a reminder was sent after 1 month 
to nonrespondents. The study was approved by the local medical ethics 
committee. Due to the intimate nature of some questions on sexual function 
patients were given the choice to respond anonymously.  
The primary outcome of this sample survey was patient satisfaction. Patients 
were asked how satisfied they were with treatment, including very satisfied, 
moderately satisfied and not satisfied. The factors and variables used for 
univariate analysis of satisfaction with SNM were age, gender, primary 
urological condition, concurrent urological, gastrointestinal and sexual 
complaints, duration of complaints before SNM and intervening medical events 
(operations). We also analyzed perception of problems with SNM (the burden 
of extra visits to the hospital and decreased efficacy), use of the switch off 
mode, change in amplitude and attitude toward scheduled yearly followup. 
When univariate interval type of data appeared to be normally distributed, the 
mean ± SD is shown. When not, the score range is provided. Univariate 
categorical data are presented as the rate and percent. To test the relationship 
between the main outcome (satisfaction with SNM) and dichotomous nominal 
data we used the Mann-Whitney test. To test the relationship between main 
outcome and polytomous nominal data we used the Kruskal-Wallis test and to 
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test it with ordinal data we used the Jonckheere-Terpstra test. The degree and 
sign of association between the main outcome and ordinal type of data were 
calculated and tested by Spearman's rank correlation coefficient (ρ). 
Multivariate analysis using satisfaction with SNM as an outcome variable was 
done with multiple (dummy) regression analysis using list wise deletion of 
missing cases, ie all cases with valid, nonmissing scores on each outcome 
variable and all predictors used in the model. Statistically significant results 
from forward selection and backward elimination techniques were combined in 
cross-section fashion to find and test the best fitting regression model. Results 
of the final model are shown including unstandardized and standardized 
coefficients, p values, etc. For this final model residual analysis was done to test 
the assumption of normality of distribution of the Student test residuals and 
inspect residual plots for digression from normality. For all data analysis SPSS® 
PC, version 16.0 was used with p <0.05 considered as statistically significant. 
 
Results 
We reviewed the records of all patients implanted between 1990 and 2007, 
excluding those who died during followup. The 13 patients in whom the device 
was removed were not included in the survey since most questionnaire items 
addressed experience with current stimulator use. A total of 275 patients at our 
clinic were sent a postal questionnaire, of whom 207 (75%) replied, including 
27 (13%) anonymously. Of the patients 5% could not be contacted since they 
had moved to a different address and 20% did not respond to the survey even 
after the reminder. Of the 180 patients who responded nonanonymously to the 
questionnaire 83% were female and 17% were male. In that group mean age at 
implantation was 48.6 ± 10.8 years (range 16 to 73) and mean age at followup 
was 56 ± 11 years. The median post-implantation period was 77 months (range 
12 to 214). Table 1 lists urological indications for SNM and the prevalence of 
self-reported comorbidity. 
 
Questionnaire results 
Most patients reported satisfaction with SNM and 80 (40%) reported having 
some concern for future life with the treatment. The most common reasons 
were decreased treatment efficacy, battery replacement procedure, medical 
need for MRI, problems with reimbursement, pregnancy and long-term 
systemic effects on the body. A total of 45 patients (22%) perceived some 
limitation due to the implant. The most common reasons were a regular feeling 
of pain, trouble with metal detectors in stores or when traveling, and not being 
able to undergo MRI. 
The reported long-term rate of SNM perceived effectiveness for urological 
complaints was high but the perceived effect on other pelvic floor disorders 
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varied. Overall 40 patients (20%) noticed fecal pattern improvement and 25 
(12%) experienced worsening of the fecal pattern. Of the 76 patients who had 1 
or more additional fecal problems before SNM 36 (47%) experienced symptom 
relief. Similarly most patients noticed no difference in sexual function. Only a 
small group reported improved libido (10 patients or 5%) and orgasm (8 or 4%) 
while 14 (7%) and 16 (8%) reported worse libido and orgasm. 
At the start of treatment all patients received a patient programmer and 
instructions how to use it but only a few reportedly used the programmer. Of 
the patients 39 (9%) turned the INS on or off on a regular basis. The most 
common reasons were undergoing operation or computerized tomography, or 
passing through metal detectors at airport customs. When patients were asked 
whether they experienced improvement by altering the amplitude, 13 (58%) 
replied that they did so. Other, less common reasons for using the programmer 
were sleeping, driving a car, sexual intercourse and sun bed use. 
Of all patients 23 (11%) and 35 (17%) reported having visited a physician due to 
temporary loss of efficacy and pain at the INS site, respectively. The most 
commonly reported reasons for temporary loss of efficacy were life stress and 
cold weather. Pain at the INS site occurred mostly when sitting on a hard chair, 
bending, walking or doing sports and lying on a hard bed, or when the INS 
implant site was touched or accidentally bumped. 
Of the patients 29% reported difficulty when passing through detectors at 
stores or airports. Of all patients who traveled by airplane 29 (23%) were 
separately searched and some were even strip searched at the airport. 
Furthermore, the ID card provided by the manufacturer, which states that the 
patient has an INS implant, was not considered authentic by the authorities in 
32 patients (25%). 
 
 Analysis Results  
Univariate  
Satisfaction with SNM was not univariately associated with patient age (ρ = 
0.147, p = 0.052), gender (ρ = 0.033, p = 0.667) or the urological indication for 
SNM treatment (F ratio 0.523, p = 0.419, Kruskal-Wallis chi-square 2.830, 3 df, p 
= 0.419). The relationship between satisfaction and self-reported comorbidity 
was tested by categorizing patients into 3 groups by the number of 
comorbidities, including none in 70 (34%), 1 in 90 (44%) and more than 1 in 45 
(22%). The response was missing in 2 patients (1.0%). Univariate analysis 
revealed an almost significant relation between comorbidity and satisfaction 
with SNM (Kruskal-Wallis chi-square 5.995, 2 df, p = 0.050). 
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Table 1. Demographic characteristics in 207 study patients 
 No. Pts (%) 
Gender:  
   M 31 (17) 
   F 149 (83) 
   Missing data due to anonymous 
response 
27 (13) 
Urological indication for SNM:  
   OAB 116 (57.4) 
   Retention 57 (28.2) 
   OAB + retention 26 (12.9) 
   Pain 3 (1.5) 
   Missing data 5 (2.4) 
Other pelvic complaints before SNM:  
   Urinary stress incontinence 55 (26.8) 
   Chronic constipation 40 (19.5) 
   Fecal incontinence 27 (13.2) 
   Irregular fecal pattern 29 (14.1) 
   Unspecified sexual dysfunction 33 (16.1) 
   Abdominal pain 58 (28.3) 
   Missing data 2 (1.0) 
 
 
Multiple dummy regression  
Table 2 lists the results. Multiple regression analysis of satisfaction with SNM 
revealed that patients with no comorbidity were significantly more satisfied 
than patients with more than 1 comorbidity (β = 0.274, p = 0.003). Satisfaction 
was positively related to the perceived effect at followup and decreased INS 
function was negatively related to satisfaction (β = −0.365, p <0.001). The way 
that patients evaluated yearly hospital outpatient visits was also related to the 
satisfaction rate. Patients who did not like the regular followup tended to have 
lower satisfaction with treatment (β = 0.251, p = 0.001). Finally, patients who 
mentioned improvement in complaints when they altered battery amplitude 
were significantly more satisfied than those without improvement and those 
who never altered the amplitude (β = −0.189, p = 0.012). This eﬀect was 
significantly higher in men (β = 0.531, p = 0.014). 
All first order interactions between the 4 main effects were tested and were 
not statistically significant except the described interaction between changing 
INS parameters and gender. Upon inspection of residual standardized plots in 
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the final model we decided that multiple (dummy) regression analysis could be 
used for data analysis. 
 
Discussion 
Sacral neuromodulation is a well established treatment for idiopathic OAB or 
nonobstructive urinary retention refractory to conservative treatment [1, 2, 4, 
8]. Long-term efficacy and adverse events have been described previously [3, 
9]. We focused on patient satisfaction and daily experience with SNM.  
Patients with OAB or urinary retention often have other concomitant lower 
urinary tract or gastrointestinal dysfunctions [8, 10]. For example, fecal 
incontinence was reported in up to 26% of patients undergoing a urodynamic 
test [10]. Of our patients, 66% reported other concomitant dysfunction, such as 
stress urinary incontinence, fecal incontinence or constipation. Although 
neuromodulation therapy was done for lower urinary tract dysfunction, 22 of 
the 46 patients (48%) with concomitant fecal problems also had symptom relief 
of their gastrointestinal problems after SNM treatment. This is comparable to 
the rate in studies specifically evaluating the effect of SNM in patients with 
bladder and bowel problems [11-13]. 
The patient satisfaction rate was high at 90% and significantly related to the 
perceived clinical effect. However, we did not include patients in whom the 
device was removed and, thus, the satisfaction rate may have been 
overestimated. However, when considering the 13 explanted cases as failures, 
the satisfaction rate in our study would still be 85%. 
 
We found no significant relationship with patient demographics, treatment 
duration or the complaint type for which SNM was indicated. Patient 
satisfaction was also shown in other ways. Of the patients 90% stated that they 
would undergo treatment again and 91% would recommend it to a friend or 
family in similar need. These results are also consistent with previous findings. 
Foster et al noted a similar satisfaction rate in 52 patients who underwent SNM 
[14]. At an average of 27 months 84% of patients was satisfied and 80% stated 
that they would undergo the same treatment again, if needed. In a quality of 
life study in 113 patients with SNM Capellano et al found that after 18 months 
90% would elect this treatment again and 100% would recommend it to a 
relative or friend [7].  
Satisfaction was significantly lower in patients with more than 1 pelvic floor 
comorbidity. This may be explained by a higher rate of a moderate SNM effect 
due to a more complex pelvic floor disorder. As mentioned, satisfaction was 
significantly related to the perceived effect of SNM. 
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Table 2. Dummy regression analysis using satisfaction with neurostimulator as dependent 
outcome variable  
 Unstandardized 
Coefficients 
   
Predictors B (95% CI) SE Standardized 
Coefficient β 
t p Value 
Constant 1.900 (1.315–
2.486) 
0.296  6.425 <0.001 
Gender (F—1 vs M—
0) 
−0.681 (−1.073–
−0.290) 
0.198 −0.398 −3.447 0.001 
Retention vs OAB 0.157 (−0.051–
0.364) 
0.105 0.119 1.497 0.137 
OAB + retention vs 
OAB 
0.245 (−0.017–
0.507) 
0.132 0.140 1.851 0.067 
No. comorbidities:      
1 vs 0 −0.069 (−0.281–
0.144) 
0.107 −0.056 −0.641 0.523 
2 or Greater vs 0 0.385 (0.136–
0.634) 
0.126 0.274 3.066 0.003 
Adjustability (yes vs 
no) 
−0.790 (−1.267–
−0.314) 
0.241 −0.645 −3.283 0.001 
Yrly followup visit 0.280 (0.115–
0.444) 
0.083 0.251 3.366 0.001 
Function evaluation 
(still working vs not) 
−0.553 (−0.777–
−0.329) 
0.113 −0.365 −4.895 <0.001 
Gender interaction 
adjustability 
0.647 (0.134–
1.161) 
0.259 0.531 2.495 0.014 
 Highly satisfied—1 and not satisfied—3 with 0.396 variance explained by the model and list wise 
deletion of 128 missing patients. 
 
The patient attitude toward yearly followup was related to the degree of 
satisfaction. Although the reason could not be deduced from this study, it may 
have been partly due to differences in travel distance. Patients who mentioned 
using the patient programmer and noticed improvement were significantly 
more satisfied than those who did not notice improvement or never used the 
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programmer. This may explained by a feeling of control over OAB or retention 
symptoms in these patients. 
Most patients were satisfied but 40% overall reported having some limitation 
or concern with SNM. Some concerns appeared realistic, such as exclusion from 
MRI after an INS was implanted, while others seemed less relevant, such as 
possible changes in future reimbursement. Also, 56% of patients reported 
having discomfort at the INS site and a significant portion of the examined 
patient population had experienced a problem with metal detectors. However, 
most patients with discomfort did not see a physician for this problem and 
problems with metal detectors were usually limited. These results show the 
importance of informed consent and providing good information before and 
after treatment. 
We describe several issues that are usually overlooked in SNM treatment in a 
large patient group with long-term followup. To our knowledge this is the first 
study focused on patient perceptions of limitations and concerns, and on the 
daily experience of patients on SNM therapy. Although some issues may seem 
trivial at first, each health care worker who deals with neuromodulation 
therapy will recognize these issues as being an important part of followup visits 
in most patients. 
The response rate of this survey was high at 75%. Thus, in our opinion this 
study provides a representative view of patient satisfaction and experience 
with SNM. However, there may have been selection bias, and the subjective 
and retrospective nature of most questions could have resulted in recall bias. 
Nevertheless, we believe that this study provides new, valuable information on 
the patient experience with SNM treatment and suggests further research 
questions. 
 
Conclusion 
Patients undergoing sacral neuromodulation therapy at our clinic showed a 
90% satisfaction rate. Satisfaction was significantly and positively related to the 
patient perceived effect, number of pelvic floor comorbidities, view of yearly 
outpatient evaluations up and experience with the patient programmer. No 
direct relationship was found with patient age, gender, therapy duration or 
type of complaint for which SNM was offered. Of patients with additional fecal 
problems before SNM 48% experienced relief of the problem. Despite the high 
satisfaction rate regularly perceived pain and discomfort at the INS site was 
reported by 56% and 40% of patients, respectively. Nine of the 10 patients who 
reported regular pain at the INS site also reported not requiring further 
treatment for it. Patient perceived limitations and concerns about SNM therapy 
were mostly related to MRI, reimbursement and pregnancy. Overall this study 
shows that sacral neuromodulation is a safe, satisfactory treatment. 
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Abstract 
The overactive bladder syndrome (OAB) negatively affects the daily life of 
many people. Conservative treatments, such as antimuscarinics, do not 
always lead to sufficient improvement of the complaints and/or are often 
associated with considerable side effects resulting in treatment failure. In 
the case of failure or intolerable side effects, sacral neuromodulation (SNM) 
and botulinum toxine are minimally invasive and reversible alternatives. 
Currently, of these alternatives only SNM with InterStim
TM
 Therapy has FDA 
approval for use in OAB patients. This review attempts to provide an update 
on the current position of SNM and botulinum toxin in the second-line 
management of adults with idiopatic OAB, based on the available clinical 
evidence concerning the efficacy and safety. 
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Introduction  
Idiopathic overactive bladder syndrome (I-OAB) is characterized by a 
combination of bladder filling symptoms: urgency with or without urgency 
urinary incontinence, usually accompanied by frequency and nocturia [1]. 
Large-scale surveys in Europe and in the US estimated an OAB prevalence of 
approximately 16-17%, of which a third (predominantly women) also have 
complaints of urgency urinary incontinence [2, 3]. Frequency and urgency 
can be as distressing as urgency incontinence, and OAB syndrome as a whole 
has a strong negative impact on the quality of life [2, 4]. 
In 2009 the International Consultation on Incontinence (ICI) published an 
algorithm intended to serve as a guide for the treatment of patients with I-
OAB (figure 1) [1]. Behavioural and lifestyle interventions are recommended 
firstly, followed by bladder and pelvic floor muscle training, or 
pharmacological treatment with antimuscarinics. However many patients 
have insufficient improvement with these treatments [4]. When 
conservative treatments fail after 8-12 weeks, alternative therapies should 
be considered [1]. These alternatives used to be invasive and irreversible 
surgical procedures, such as bladder augmentation or urinary diversion. 
Currently new and minimally invasive techniques are available such as sacral 
neuromodulation (SNM; recommended by ICI – level of evidence A), 
posterior tibial nerve stimulation (not recommended by ICI – insufficient 
scientific data) and intradetrusor injection of botulinum toxin (BTX) (BTX; ICI 
– off label treatment – level of evidence C) [1].   
Because both SNM and BTX injections are increasingly being applied in 
clinical practice, an overview is given on the available scientific and clinical 
evidence on safety and efficacy. The position of SNM and BTX as second-line 
treatment options for adults with I-OAB is discussed. 
 
Botulinum toxin  
Introduction 
BTX is a protein that is produced by the anaerobic Gram-positive bacteria 
Clostridium botulinum. Local injection of BTX leads to temporary chemical 
denervation and loss or reduction of nerve cell activity at the tissue. Use of 
BTX as a muscle relaxant is indicated for various neurological disorders, such 
as torticollis spasmodica or other spastic diseases of the musculoskeletal 
system, serious primary caudal hyperhydrosis, and for aesthetic reasons. 
Among urologist there is a growing popularity of products containing BTX 
mostly type A in particular Botox® (Allergan, USA) and Dysport® (high-value 
biotech, France).  
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Working mechanism  
The effect of BTX in I-OAB patients is based on a temporary inhibition of the 
neuromuscular nerve signals, which leads to relaxation of the smooth 
muscles in the bladder. Previously, the main effect was considered as 
temporary blockage of presynaptic vesicle release which decreases 
acetylcholine to the neuromuscular junction. Recent research shows 
expanded effects such as inhibited release of other transmitters 
(neuropeptide substance P, APT) and downregulation of the axonal 
expression of purinergic p2x3-and capsaicin-TPRV1-receptors of the nerve 
endings in the (sub)urothelium, contributing to the afferent desensitization 
[5]. Besides an effect on the afferent bladder signals, it is very likely that 
efferent nerves are also being affected. BTX decreases detrusor pressure 
during both the filling and the voiding phase, and may increase the post-void 
residual volume [5]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment protocol 
There is no standard protocol for the application of BTX. In most published 
trials, 100-300 U Botox or 500 U Dysport are injected at 10-30 different sites 
         Figure 1: Algorithm derived from ‘evidence-based’ recommendations of the ICI from 2008 
Urgency  
Incontinence 
• Neuromodulation (Grade A) 
• Botulinum toxin (Grade C) 
• Bladder augmentation (Grade C) 
Specialized management of Urinary Incontinence 
• Correct anatomic BOO 
• α-blockers (male) 
• 5α-reductase inhibitors 
(male) 
• Antimuscarinic  
With bladder outlet 
obstruction (BOO) 
• Intermittent 
catheterization 
• Antimuscarinic  
With underactive 
detrusor 
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of the bladder wall (table 1) [6-11]. Injections can be performed under local 
or general anaesthesia. The possibility of using no anaesthesia at all is also 
being tested [12]. In terms of injection technique, a comparative study 
showed a significantly better effect after 9 months when BTX was injected 
into the detrusor muscle compared to injection into the bladder 
suburothelium. Both detrusor or suburothelium injection in the bladder 
body were better compared to suburothelium injection into bladder base 
[13]. However injection into the bladder base reduced the urgency episodes 
significantly, while the other sites did not. In most trials, the trigone is not 
injected to eliminate risk of iatrogenic vesicoureteral reflux. However, recent 
studies argue against this postulation [13-15].  
Dose-response studies show that low dosages (100 instead of 150- 300 U) 
injected into the detrusor or suburothelium, lead to a significant reduction 
of the side effects, but also to a reduction in the duration of the therapeutic 
effect and the quality of life scores [16, 17].  
 
 
 
Effectiveness 
Currently four randomized controlled trials (RCT) have been published. The 
first one used BTX type B and showed significant improvements; however, 
the effect was of short-term (6 weeks) [18]. The other three trials used BTX 
type A [6, 19, 20].  Several nonrandomized, prospective open-label studies 
have investigated the value of BTX treatment in I-OAB patients. 
Unfortunately, in most studies, the patient numbers are limited (10 to 30 
patients), reducing the reliability of the results. Only three studies cover 
relatively large groups of patients [8, 21, 22]. 
Comparison of all of these studies is difficult due to the differences in the 
methodology and parameters used. All the RCT trials and the open-label 
studies show promising results (table 2). Generally, around 80% of the 
patients treated with BTX experience improvement. The number of voids 
per day decreases on an average with 12-53%, urgency episodes per day 
Table 1. Technique overview 
 First author Patients        
RCT Placebo BTX Dose, U Injections Injection site 
   Sahai [6] 18 16 200  20 bladder wall 
   Flynn [20]  7 15 200/300  8-10 detrusor 
   Brubaker [19] 15 28 200  15-20 detrusor 
Observational           
   Kalsi [8] x 38 200  20-30 detrusor 
   Khan [21] x 81 200  20 detrusor 
   Schmid [22] x 220 100 30 suburothelium 
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with 28-70%, and incontinence episodes per day with 35-87%. The maximum 
cystometric capacity increased by an average by 45%. The Impact 
Questionnaire-Short Form score decreased by a mean of 54-57%, and the 
Urological Distress Inventory score decreased with a mean of 38-64%. 
Almost all parameters used in the RCT trials showed significant 
improvements compared with placebo.       
Long-term follow-up trials show an average recurrence rate of 27-66%, with 
a mean duration of clinical improvements of 6-14 months and a mean 
interinjection interval of 14- 23 months (table 3). While some patients have 
a temporary effect, some patients seem to be ‘cured’ after one or two 
treatments. Khan et al. showed a cure rate of 10% and Schmid et al of 38% 
after the first injection while another 33% showed a ‘permanent’ good effect 
when combining the treatment with anticholinergics [21-22].  
A study on the satisfaction of patients who underwent BTX showed that 
among 38 patients with neurogenic or I-OAB, 93% of the patients would 
undergo the procedure again [23]. Overall, patients were satisfied giving the 
treatment an average score of 6.9 in a satisfaction scale between 0 and 10. 
Furthermore, 90% of the patients reported clear improvement in their 
voiding situation, and 6.7% had adverse events.   
 
Table 2. Effect of BTX 
First 
author 
Follow-
up 
General 
improve-
ment 
Voids/ 
day 
Urgency/ 
day 
IE/ 
day 
100% 
continence 
Pads/ 
day 
24-
hour 
pad 
weight MCC 
IIQ-7 
score 
UDI-
6 
score 
Sahai [6] 
12 
weeks   -40 -70 -70 50     45 -57 -53 
Flynn 
[20] 
6 
weeks   -12   -57   -50 -45 x -67 -38 
Brubaker 
[19] 
12 
months 79    -87           -39 
Kalsi [8] 
16 
weeks 79 -18.20 -28.10 -35       46     
Khan 
[21]  
4 
weeks                -54 -64 
Schmid 
[22] 
9 
months 86 -53     85 -90    63     
Figures indicate percentages, unless otherwise indicated. IE = Incontinence episodes; MCC = maximum cystometric 
capacity; 
IIQ-7 = Impact Questionnaire-Short Form; UDI = Urogenital Distress Inventory-Short Form; x = no significant difference 
vs. placebo 
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Safety  
BTX is generally well tolerated. No major complications were noted in 
anyRCTs or large open-label studies (table 4). The most common adverse 
events were high post-void residual (19-43% depending on criteria used) 
requiring clean intermittent self-catheterization (4%-43% depending on the 
criteria used) and urinary tract infection (10-43%) [6, 22, 24]. However, this 
incidence seems to be dose dependent. A dose-effect study among 313 I-
OAB patients who received either placebo, 50, 100, 150, 200, or 300 U BTX 
showed an incidence of post void residual (>200cc) of 0%, 12.5%, 14.5%, 
20.0%, 28.8%, 27.3%  respectively [17].  
Aside from local side effects of BTX, muscular weakness as a result of 
unintentional dissemination of the toxin outside the target area may also 
occur. Between 2003 and 2007, four adverse events were reported in a 
Danish registry after BTX treatment for urological interventions [25]. 
Although the real incidence cannot be deduced from these data, it is 
estimated around 10/10,000 interventions. All adverse events involved 
muscle weakness, two were throughout the whole body, one in the arms 
and one in the thoracic muscles necessitating artificial respiration. The latter 
occurred in a patient with neurogenic bladder dysfunction. In general, 
serious side effects can occur such as problems with speech, swallowing 
(dysphagia) or breathing. Mortality after BTX treatment has been reported 
before, although rarely and only in patients with known neurological 
disease. Because of this, manufacturers of products containing BTX, after 
consultation with European regulators, issued a warning about the safety in 
France, Denmark, Spain, Germany and the UK [25-29].  
The safety of repeated injections is rarely or not described. Although the 
impact of repeated injections on the bladder compliance is unknown, no 
change in compliance has been demonstrated after up to three injections 
Table 3. Reinjections   
First author 
Follow-
up 
Recurrence 
rate, %  
Duration of 
clinical 
improvements 
Interinjection 
interval "Cure", % 
Sahai [6] 
9 
months   6 months     
Flynn [20] - - - - - 
Brubaker [19] 
13 
months 66 307 days     
Kalsi [8] 
27 
months   13.86 months 1.9 years 
16.7 (> 27 
months) 
Khan [21] 2,8 years 57   14 months 
10 ( > 14 
months) 
Schmid [22] 7 years 26.8 9 months 13.5 months 38 
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[30]. Although BTX in its present form has a small antigenic potential and 
some immune resistance has been reported on I-OAB and BTX, an immune 
response can occur after repeated injection, and ultimately even 
tachyphylaxis [10, 31]. Schulte-Baukloh et al reported the presence of BTX-
antigen among 8 out of 25 patients after two injections [31]. Further analysis 
showed a possible correlation between the presence of BTX-antigen and the 
reduction in treatment effect. To minimize the risk of immune resistance 
and response as much as possible, it is advisable to wait at least 3 months 
between injections, and to choose the lowest dose that will achieve the 
desired clinical effects [32].  
 
Table 4.  Most common adverse events associated with BTX therapy 
First author UTI, % AUR, % Mean PVR, ml De novo PVR, % CIC, % 
Sahai [6] 20.50 0 44 => 51 37,5 (>150 ml) 37.5 
Flynn [20] 13 ND  25 => 107 26,6 (>200 ml) 6.7 
Brubaker 
[19] 44 ND  ND 43 (>200 ml) 32 
Kalsi [8] - - - - - 
Khan [21] 15 ND  ND 43 (>100 ml) 43 
Schmid [22] 10 4 (>400ml) 21 => 85  19 (>150 ml) 4 
UTI = Urinary tract infection; AUR = acute urinary retention; PVR = post-void residual urine; CIC = 
clean intermittent catheterization. 
 
Sacral neuromodulation 
Introduction 
SNM comprises the stimulation of the sacral nerves that innervate the 
bladder, urethral sphincter and pelvic floor muscles. Stimulation electrodes 
are placed at the level of the third sacral nerve (S3) and connected to a 
electrical stimulator that is implanted. The implantable nerve stimulator 
(INS) that is being used for SNM therapy uses the Interstim
tm
-technology 
(Medtronic, Minneapolis, Minn., USA). 
The indications for SNM therapy are I-OAB, nonobstructive urinary 
retention, faecal incontinence and chronic constipation. 
 
Working mechanism  
The precise mechanism of action of SNM is still not entirely clear. It is 
assumed that SNM affects the ‘neuroaxis’ at various levels and restores the 
balance between excitatory and inhibitory regulation at various locations 
within the peripheral and central nervous system [33]. Furthermore, SNM 
may also activate the afferent bladder somatosensors which run to the 
micturation centre in the brain stem, and/or activate the hypogastric 
sympathic nerves [34]. 
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Treatment protocol 
Before implanting the INS, a screening test is performed to assess the clinical 
effect of sacral nerve stimulation. There are two test protocols. The 
percutaneous nerve evaluation (PNE) test uses a non-anchored test lead 
placed into the S3 foramen and connected to an external stimulator. The 
test period extends between 4 and 14 days, after which the test lead is 
removed. The procedure is usually done in an outpatient setting. The overall 
response rate for PNE is around 55% [35, 36]. Lead migration is considered 
the main factor leading to false negative results [37, 38].  
The definitive lead electrode has self-anchoring tines that reduce the risk of 
migration. These leads can also be used for testing. The lead is usually 
placed into the S3 foramen under general anaesthesia (although some 
centres also use local anaesthesia in an outpatient setting), correct 
positioning is guided with fluoroscopy, the lead is subcutaneously tunnelled 
and connected subcutaneously to a temporary extension lead that exits the 
skin and is connected to an external pulse generator. This procedure enables 
test periods of up to 3-4 weeks. If the patient has a good response during 
the test, the present lead is connected to an internal nerve stimulator. This 
procedure is done under local or general anaesthesia. Because of the 
decreased risk of migration and the longer test duration, this test has a 
higher response rate. According to a study of Kessler et al. prolonged 
screening with the tined lead has a response rate of 67% compared to 43% 
during PNE testing [39]. The costs for test protocol with the tined leads are 
much higher compared to the PNE test. Currently the use of either one of 
the two screenings option is arbitrary.  
 
Effectiveness  
There is convincing evidence for the success of SNM with the Interstim 
technique for refractory I-OAB. Three RCTs (two on patients with urgency 
incontinence and one on patients with urgency frequency) [35, 36, 40] and 
many articles on long-term observational studies have been published [41-
45]. Good clinical response is reported between 64 and 88% of all patients. 
All parameters reported, showed significant improvement compared to the 
placebo group: a 23-46% decrease in the number of voids per day, 44-77% 
increase in the average voided volume, 56-90% decrease in incontinence 
episodes per day, 64-100% decrease in pads and 39% increase in maximum 
cystometric capacity (table 5).  
A 5-year follow-up study on 121 patients with refractory I-OAB showed 
persistence of the clinical success in  the long-term: 84% of the patients with 
urgency incontinence and 71% of the patients with urgency/frequency who 
had a successful outcome 1 year after implantation continued to have a 
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successfully outcome after five years [43]. A study on the tined lead 
procedure in 21 patients with I-OAB showed clinical success after an average 
of 15.5 months around 90% [45]. In all reported studies, clinical success is 
defined as a > 50% improvement in one of the relevant urinary voiding 
parameters. 
Satisfaction and quality of life scores after SNM have also been studied. 
Cappellano et al. showed a significant improvement in the quality of life 
score in patients with urgency incontinence who underwent SNM from a 
mean score of 34 to 76 [46]. At 18 months follow-up they were asked 
whether they would undergo this treatment again. 90% responded yes and 
100% would recommend it to a relative or friend. Foster et al. asked 49 
patients with urgency incontinence on their satisfaction with SNM 
treatment. The majority of the patients were satisfied (84%) and would “do 
it all over again” (80%) [47]. 
 
 
Table 5. Short-term results of treatment with sacral neuromodulation or with placebo among 
patients with overactive bladder. 
First author 
Follow-
up, 
months 
General 
improvement, 
% 
Voids/ 
day, 
% 
Voided 
vol., % 
IE/day, 
% 
Proportion 
of group 
with 100% 
continence, 
% 
Pads/day, 
% 
MCC, 
% 
Weil [36] 6        -90 56 -92 39 
Schmidt 
[35] 6        -73 47 -82   
Hassouna 
[40] 12  88 -46 77         
van 
Kerrebroeck 
[43] 49    -23 79 -56   -64   
van 
Voskuilen 
[44]  64,2  64             
Sutherland 
[42] 22  69 -35   -88 50 -100   
Voskuilen 
[45]  15,5  80 -38 44 -65       
Hijaz [41] 16  75             
 
 
Safety 
Adverse events are usually related to the implant procedure, the presence of 
the implant or of undesirable stimulation. The most common adverse event 
reported is pain at the implant site. The occurrence in most studies varies 
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between 3 and 42% (table 6) [22, 36, 40-45]. Other adverse events reported 
are lead migration (1-21%), bowel dysfunction (4-7%) and infection (4-10%). 
Technical improvements throughout the years have decreased the incidence 
of adverse events significantly. Two important improvements were the 
introduction of tined leads (leads with hooks) and the gluteal placement of 
the INS instead of abdominal. Ever since, both the incidence of adverse 
events and the reoperation rate per implanted patient have decreased (Fig. 
2) [44].  
The majority of adverse events do not require surgical intervention. 
Decreased efficacy because of to electrode migration and undesirable 
stimulation can easily be solved by reprogramming of the INS. A 
retrospective analysis among 83 implanted patients with a reduced response 
or complications, such as pain at the INS site, showed that 18% of the cases 
could be helped conservatively [42]. Furthermore, the incidence of adverse 
events is lower with the new tined leads in comparison with non-tined leads 
(28% and 73%, respectively) [42]. A study among 235 patients confirmed 
that tined leads migrated less often, which occurred among 5 patients 
(2.1%) [48]. The available data indicate that the further development and 
optimization of SNM limits the risk of adverse events.  
  
Table 6. Most frequent adverse events associated with SNM therapy 
First author 
Pain at 
implant 
site, % 
Lead 
migration, 
% Other pain, % 
Bowel 
function 
disturbance, 
% 
Infection, 
% 
Weil [36] 42 21 18 (leg) 5   
Schmidt [35] 33 13   5 4 
Hassouna [40]       4   
van 
Kerrebroeck 
[43] 19 5 7.9 (lead site) 7 8 
van Voskuilen 
[44]  28 7 
43 (pain or 
discomfort)   4 
Sutherland 
[42] 15     5 10 
Voskuilen [45]  7 3 3 (leg stimulation)     
Hijaz [41] 3 1     5 
 
 
Other considerations, SNM versus BTX  
Both SNM and BTX have similar effectiveness rates and both have relatively 
small, treatable and nonpermanent side effects. When having to choose 
between SNM and BTX, urologists may rely on other data such as long term 
safety and effect data and cost-effectiveness data.  
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Recently, three cost-effectiveness studies have been published on SNM 
versus BTX, all three in the form of abstract. Arlandis and colleages 
compared SNM with BTX from a public health point of view in Spain, Leong’s 
group compared SNM with BTX from a hospital point of view in the 
Netherlands, and Leng’s group compared SNM with BTX from a public health 
point of view in North America. Both Arlandis’ group and Leong’s group 
concluded that SNM is cost-effective compared with BTX, whereas Leng and 
co-workers concluded that BTX treatment dominated SNM (more effect at 
less cost), even after repeated sensitivity analysis. More data on these 
abstracts is required to explain these contradictory results.  
Another way of choosing between SNM and BTX is a pati
approach. Patients with comorbidities in the pelvic region may be better off 
with SNM. Some studies have shown that other urinary voiding disorders 
such as urinary retention are present in 1 out of 3 I
26% of women with lower urinary tract disorders also have faecal 
incontinence [49, 50]. SNM is also approved for the treatment of ur
retention, faecal incontinence and chronic constipation 
studies have shown that patients can experience relief for both OAB and 
other pelvic floor disorders at the same time when treated with SNM 
54]. On the other hand patients who need regular MRI scans may be better 
off with BTX treatment, because so far SNM is not MRI proof. 
 
Figure 2. Average number of adverse events and surgical revision per 
implanted patient.[44]
 
Conclusion 
OAB has a significant impact on the quality of life in both men and women. If 
conservative treatments are not effective, then there are various second
line treatment options available. SNM and BTX therapy are the most 
commonly used. Both of these treatments have similar effectiveness rates 
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and both have relatively small, treatable and nonpermanent side effects. 
Cost-effectiveness analyses have shown contradictory results. BTX treatment 
has not yet been officially approved for urological disorders due to lack of 
long-term effect and safety data and lack of consensus regarding the proper 
dosage and the injection method. However, all BTX studies on patients with 
I-OAB are promising and point to the direction of approval. Until then, SNM 
is the only minimal invasive option approved for I-OAB patients who are 
refractory to conservative treatment.   
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Summary 
Objectives: To assess and compare the costs and effects value of either 
starting with sacral neuromodulation (SNM) or botulinum toxin A (BTX) 
treatment in patients with refractory idiopathic overactive bladder from a 
societal perspective.   
 
Materials and Methods: An economic model comparing SNM with BTX was 
developed. A clinical relevant effect (i.e. success) was defined as 50% or 
greater reduction in incontinence episodes or urgency frequency symptoms. 
Information on the clinical effectiveness of the two treatments and on the 
course of the disease with the two treatments were based primarily on 
published literature and, when required, on expert opinion. Both treatments 
were assumed to be performed under general anesthesia and, for SNM 
treatment, first-stage tined lead test was used. All costs were based on 
national data from the year 2008. Analyses from the societal perspective 
were conducted for a 5-year duration. Costs were discounted at 4% and 
effects at 1.5%. In addition, different modelling scenarios were used to 
determine if any changes in the results obtained. 
 
Results: Starting with SNM resulted in a higher quality adjusted life year 
(QALY) gain (difference of 0.23) and a higher cost (difference of €6,428) 
compared to starting with BTX. The corresponding incremental cost-
effectiveness ratio was €27 991/QALY. The probability of this ratio being cost 
effective (e.g. under €40 000/QALY) is 88%. SNM starts to be cost-effective 
after four years. SNM was not cost-effective in some other scenarios, such 
as when BTX was conducted under local anaesthesia or when percutaneous 
nerve evaluation or bilateral testing was used for SNM.    
 
Conclusions: Starting with SNM, treatment is cost-effective after 5 years 
compared to BTX. However, in some scenarios, such as the use of local 
anaesthesia for BTX treatment and SNM percutaneous nerve evaluation or 
bilateral test, SNM was not cost-effective.   
 
Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A 
treatment for patients with idiopathic overactive bladder. 
 
 91 
Introduction 
Overactive bladder syndrome (OAB) is a combination of urinary symptoms 
and is defined as urgency with or without urge incontinence, usually with 
frequency and nocturia [1]. Estimated prevalence is between 12-17% of 
which one-third of cases experience urgency urinary incontinence [2-5]. This 
syndrome significantly impacts the patient’s health-related quality of life 
(HRQL) and the costs for OAB management are estimated between €250 
million and €4.2 billon in selected European countries [6-9].  
 
Treatment of patients with OAB is complex and international guidelines 
suggest lifestyle interventions, pelvic floor muscle training, bladder 
retraining and medication (anti-muscarinics) as first line treatment options 
[1]. When these therapies fail or are intolerable for patients, other more 
invasive options are available. Sacral neuromodulation (SNM) and Botulinum 
toxin A (BTX) are two minimal invasive treatment options that have shown 
positive results in clinical trials and should be considered before more 
invasive surgery, such as bladder augmentation [10-13].  
Besides clinical effectiveness, cost-effectiveness should also be considered 
when making a choice between SNM and BTX. Cost-effectiveness analysis 
compares the combination of health outcomes and resource costs for 
different health technologies. It applies clinical outcomes and data on 
resources from clinical trials or when these resources are unknown or 
insufficiently documented through modelling techniques [14]. Previously, it 
has been shown that BTX is cost-effective compared to conservative 
treatment [15]. SNM has not been compared to conservative treatment, 
although, in a cost-consequence study, Aboseif et al. showed that drug, 
diagnostic and outpatient visit costs were significantly reduced after SNM 
treatment [16].  
The present study aimed to asses and compare the costs and effects value of 
either starting treatment with SNM or BTX in patients with refractory 
idiopathic OAB from a societal perspective.   
 
Material and Methods 
Decision Model 
The cost-effectiveness analysis from a societal perspective in the 
Netherlands was performed using a probabilistic Markov analytic model. The 
study population consisted of patients with refractory idiopathic OAB who 
failed conservative treatment and the analysis was conducted over 5 years. 
The model compares two different treatment pathways: one that starts with 
BTX and the other with SNM including its test procedures. If a patient failed 
a therapy then the next successive treatment option according to treatment 
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transition rates specified in the model figure was given 
was assumed that 75% of the failures would receive the alternative 
treatment (either SNM or BTX) and 25% would receive no further treatment. 
If a patient failed both treatment options then no 
offered. Success would be followed by repeat with the same therapy when 
necessary. 
The decision model was constructed and analyzed with Microsoft Office 
Excel software (Microsoft Corp., Redmond, WA, USA). 
 
Figure 1.  Model figure  
 
Parameter estimates:  
Parameter estimates are based on the literature data if available (Table 1). 
The screening test used for SNM treatment was the first
test. The success rate was estimated at 75% and the 1
90% [17, 18]. The yearly drop-out rate for SNM was 4.3%, which was based 
on data of two previous long-term SNM studies 
SNM retreatment in the form of battery replacement as 
was estimated at a mean (range) of 7 (5-10) years preceded by a period of 3 
months with loss of effect (average time between start complaint, 
outpatient clinic and actual battery replacement). The adverse event rates 
for each patient undergoing SNM treatment included 16% for surgical 
revision as a result of pain or loss of effect and 7.5% for removal of system 
as a result of pain, infection or loss of effect 
(Fig 1). In this case it 
further treatment was 
 
 
-stage tined lead 
-year success rate at 
[12, 18]. Time interval for 
a result of depletion 
[18].  
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The success rate for BTX treatment was estimated at 79% [19]. Because data 
on the yearly drop-out rate for BTX is lacking, an assumption was made that 
BTX drop-out rate is equal to SNM drop-out rate. The adverse event rates for 
each patient undergoing BTX was estimated at 38% for urinary retention 
requiring intermittent self catheterization and 41% for urinary tract infection 
requiring antibiotic treatments [10, 19, 20]. In addition, expert opinion was 
obtained through a survey that was sent to 13 urologists in the Netherlands 
who perform BTX and SNM to estimate effect and treatment duration. On 
the basis of this survey, it was assumed that treatment effect lasted for 9 
months, patients were fully symptomatic for 3 months and retreatment was 
performed every 12 months.  
 
Cost inputs 
The cost analysis considered direct costs to the society in the Netherlands in 
2008 in Euros. Costs were accounted for healthcare resource consumption 
during pretreatment, treatment, symptomatic periods, follow-up treatment, 
treatment of adverse events, and treatment after failure. On the basis of 
common practice in the Netherlands, both SNM test and definitive 
implantation procedure were performed in an operating room or at an 
ambulatory surgical center, with procedures each lasting 45 minutes, 
followed by inpatient stay for the definitive implantation. On the basis of 
common practice in the Netherlands, the BTX procedure included the use of 
200 U of Botox® (Allergan, Irvin, CA, USA) and was performed at an 
operating room or at an ambulatory surgical center, which took 30 min, 
followed by inpatient stay. SNM adverse events costs included costs for the 
use of antibiotics, removal and replacement of lead or implantable pulse 
generator device and inpatient stay. BTX adverse events costs included 
catheter use, urine culture and antibiotics. Unit costs for treatment and 
concomitant medications, investigations, surgical procedures and disease 
management were obtained from published sources [21]. These costs were 
then multiplied by rates of resource use consumption, aiming to derive 
direct costs for the initiation and each outcome of treatment (table 2). A 
discount rate of 4% per annum was applied to account for the present value 
of the future stream of costs [22]. 
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Outcomes 
Treatment outcomes included success (> 50% improvement in number of 
leakages, pad use, and number of voids or volume per void) or failure (< 50% 
improvement). The utility values were 0.73 for incontinence episodes or no 
treatment improvement and 0.95 for no incontinence or treatment 
improvement [23]. Quality adjusted life years (QALYs) were discounted at an 
annual rate of 1.5% per year [22]. The incremental costs were compared 
with the incremental effectiveness (e.g. QALYs) to obtain incremental cost-
Table 1. Input parameters per patient  
Variable Value Range  
Basecase scenario    
Utility value improvement 0.95 0.90-1.0 
Utility value no improvement 0.73 0.48-0.98 
Success rate SNM test 75% 65 - 80 
SNM Battery replacement 1/7 years 5 – 12 
SNM Loss of effect period  3months/7years 0 - 5  
SNM Surgical revision 16% 15-33 
SNM Removal of system 7.5% 4-8 
Initial success BTX 79% 76 – 95 
BTX Retreatment rate  1/12months 7 – 14 
BTX loss of effect period before retreatment 3months/years 0.5 – 4 
Urinary retention requiring CIC 38%  19.3-43 
Urinary tract infection 41%  6.5-44 
Yearly drop-out rate SNM or BTX 4.3%  SD=0.0043 
Pads use ‘improvement’ 1/day  
Pads use ‘no improvement’ 7/day   
SNM pre-procedure costs (€) 278   21 – 347 
1
st
 stage tined lead procedure (incl. material) costs (€) 3445 2339 – 3744 
2
nd
 stage tined lead procedure (incl. Interstim 1) costs (€) 9150 7862 – 9498 
SNM surgical revision costs (€) 2590  1483 –  2889 
SNM surgical removal/replacement costs when infected 
(€) 11,448  8874 - 12,144  
BTX pre-procedure costs (€) 290  22 - 362  
BTX procedure (incl. 200 U BTX) costs (€) 1564 117 – 1839 
Urinary Retention costs (€) 449  34 - 561 
UTI costs (€) 100  8 – 125 
Out-patient follow-up costs (€) 70 5 - 88  
Pads costs (€) 0.45 0.23 - 1.83  
Other scenarios    
PNE test procedure (incl. material) (€) 439 182 – 523 
2
nd
 stage tined lead procedure with Interstim 2 (€) 11,346 8772 - 12,042 
Bilateral 1
st
 stage tined lead procedure (incl. material) (€) 6491 4647 - 6989 
Local anesthesia 2
nd
 stage tined lead procedure  (€) 8699 7828 – 8934 
Local anesthesia BTX procedure (including BTX)  (€) 839 492 - 933 
BTX, botulinum toxin A; CIC, clean intermittent catheterization; PNE, peripheral nerve evaluation; SNM, 
sacral neuromodulation. 
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effectiveness ratios (ICERs) for SNM versus BTX. An ICER of less than €40 
000/QALY was considered cost-effective, which is a well accepted threshold 
to define cost-effectiveness [24].  
 
Different scenarios/ one-way sensitivity analysis 
To study the impact of treatment period, the duration of the study was 
shortened to 1, 2, 3, 4 and lengthened to 10 years, assuming the effects and 
costs would stay the same. On the basis of the most common situation in 
the Netherlands, the base case scenario for both SNM and BTX in the 
present included the use of operation room or ambulatory surgical centre 
followed by inpatient stay and the use of the tined lead procedure (TLP) as 
SNM test and Interstim 1 as the SNM battery model. However, different 
hospitals use different type of devices for SNM therapy and have different 
protocols regarding use of operation room or inpatient stay. Therefore, 
several options were evaluated: use of peripheral nerve evaluation (PNE) 
(response rate 55%); use of bilateral PNE; use of bilateral TLP; use of battery 
model Interstim 2; SNM procedure placed under local anesthesia in 
operation room without inpatient stay; BTX procedure performed under 
local anaesthesia outside the operation room without inpatient stay; and 
both procedures under local anaesthesia [13, 25].  
Because proper utility value for urinary incontinence is lacking different 
values (e.g. 0.80, 0.85, 0.90, 0.94) were used to determine its impact on the 
results. The yearly drop-out rate for BTX is still unknown. Therefore different 
drop-out rates, e.g. 2% and 6%, were used to determine any impact on the 
results obtained.   
Uncertainty of the input parameters was addressed in a second-order 
Monte Carlo simulation with 1000 random draws and one-way sensitivity 
analyses to assess the robustness of the model [26]. For all analyses, the 
probability of cost-effectiveness was determined by drawing cost-
effectiveness acceptability curves.  
 
Results 
The results of the CE analysis are given in Table 2. The base case of the cost-
effectiveness analysis over a 5-year period showed 4.95 QALYs for SNM 
compared to 4.72 for BTX. Additional effectiveness for SNM was 0.23 (range 
0.11-0.35) QALYs per patient. The 5-year costs were €25 780 for SNM and 
€19 353 for BTX, resulting in additional costs of €6,428 (95% CI, €3131-11 
142) per patient for SNM. The corresponding ICER was €27 991/QALY. The 
cost-effectiveness acceptability curve shows that the probability of this ratio 
to be cost-effective (e.g. at a maximum of €40.000/QALY) is 88% (Fig. 2).  
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Varying durations of between 1 and 10 years showed that, after 1 year, SNM 
is inferior to BTX. However, the ICER drops from €84,660/QALY in year 2 to 
€14,493/QALY in year 10 (Fig. 2 and Table 2). Starting treatment with SNM 
becomes cost-effective (ICER > €40.000) after 4 years.  
Sensitivity analyses showed that over a 5-year time horizon the ICER 
remained below the €40.000 threshold for cost-effectiveness when SNM 
was performed under local anaesthesia whereas BTX was not, when the 
drop-out rate was changed to 2% or 6% and when the utility for 
incontinence or no improvement was changed to 0.80 (Fig. 3-6 and Table 2). 
SNM was not cost-effective (ICER > €40.000) in all other scenarios, such as 
when BTX was conducted under local anaesthesia or when PNE or bilateral 
testing was used for SNM (Fig. 3-6 and Table 2).    
 
 
Table 2.  Results base case and sensitivity analyses 
 SNM therapy BTX therapy Incremental iCER 
€/QALY 
 
Cost € QALY Cost € QALY Cost € QALY 
1 year 
20,105 1.66 9,359 1.66 10,745 -0.01 
SNM 
dominated 
2 year 21,444 2.51 11,524 2.39 9,920 0.12 84,660 
3 year 22,840 3.34 14,173 3.18 8,666 0.16 54,291 
4 year 24,288 4.15 16,793 3.96 7,495 0.20 38,327 
5 year (Base case scenario) 25,780 4.95 19,353 4.72 6,428 0.23 27,991 
6 year 27,307 5.73 21,851 5.47 5,456 0.26 20,827 
7 year 32,192 6.49 24,289 6.20 7,903 0.29 27,010 
8 year 33,763 7.24 26,848 6.92 6,916 0.32 21,502 
9 year 35,347 7.98 29,194 7.63 6,153 0.35 17,623 
10 year 36,878 8.69 31,485 8.32 5,393 0.37 14,493 
PNE test  22,264 4.72 19,189 4.72 3,075 0.00 3,219,121 
Bilateral PNE test 22,775 4.72 19,223 4.72 3,552 0.00 3,717,822 
Interstim 2  31,111 4.95 19,406 4.72 11,706 0.23 50,974 
Bilateral 1
st
 stage (Interstim 1)  30,366 4.95 19,599 4.72 10,767 0.23 46,888 
Bilateral 1
st
 stage (Interstim 2) 35,696 4.95 19,652 4.72 16,045 0.23 69,870 
Local anesthesia (SNM only)  24,748 4.95 19,304 4.72 5,444 0.23 23,707 
Local anesthesia (BTX only)  25,376 4.95 13,978 4.72 11,398 0.23 49,634 
Local anesthesia (SNM and BTX) 24,343 4.95 13,929 4.72 10,414 0.23 45,350 
Drop out rate 2% 25,765 4.95 19,196 4.79 6,569 0.17 39,265 
Drop out rate 6% 25,791 4.95 19,463 4.68 6,328 0.27 23,121 
Utility ‘no improvement’ 0.80  25,780 5.03 19,353 4.87 6,428 0.17 38,572 
Utility ‘no improvement’ 0.85  25,780 5.09 19,353 4.97 6,428 0.12 52,837 
Utility ‘no improvement’ 0.90  25,780 5.15 19,353 5.08 6,428 0.08 83,847 
Utility ‘no improvement’ 0.94 25,780 5.20 19,353 5.16 6,428 0.04 158,058 
BTX, botulinum toxin A; CIC, clean intermittent catheterization; PNE, peripheral nerve evaluation; SNM, sacral 
neuromodulation. 
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Figure 2. Acceptability curves of different follow-up years  
 
 
 
Figure 3. Acceptability curves of different devices. 
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Figure 4. Acceptability curves of different procedure protocols.
 
 
Figure 5. Acceptability curves of different drop out rates BTX. 
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Figure 6. Acceptability curves of different utility values.  
 
 
 
Discussion 
According to our analysis, a similar number of patients are successfully 
treated after 5 years, independent of starting treatment with either SNM or 
BTX. However because of the repeated loss of effect and thus loss of QALY 
between BTX reinjections, the overall QALYs gained after 5 years were lower 
for BTX than for SNM. With respect to costs, BTX treatment is cheaper, 
despite the need to repeat the treatment on a yearly basis. The ICER was 
€27 991, which is below the threshold used in most industrialized countries, 
implying that starting with SNM treatment is cost-effective compared to 
BTX.  
The first publication on cost-effectiveness comparing SNM with BTX 
treatment concluded that BTX is more cost effective than SNM over a 2-year 
period [23]. Considering the retreatment rate for Botox and the stable long-
term efficacy of SNM, we consider that a 2-year period is too short to make 
an adequate comparison [12]. Therefore a 5-year duration was used in the 
present study and the results obtained show that SNM becomes cost 
effective (ICER < €40.000) from the third treatment year onward.  
Studies comparing SNM and BTX in terms of long-term effectiveness and 
complication rate, as well as their effect on the HRQL, are lacking. In 
prospective studies, patients with SNM have been followed for 5 years and 
with BTX for 1 year. In retrospective studies, SNM patients have been 
followed for more than 11 years and BTX patients for seven years [27, 28]. 
Therefore, we had to make some essential assumptions. Our model 
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extrapolates the effect rate, the utility values and the yearly drop-out rate 
between 1 and 10 years by keeping them constant, which may not be an 
accurate representation of the real treatment benefit. Sensitivity analysis 
shows that starting treatment with SNM is cost-effective irrespective of the 
BTX drop-out rate.  
The utility value for OAB is hard to determine and is dependent on the type 
of HRQL questionnaire used. This is because most non-disease-specific HRQL 
questionnaires focus on physical problems, whereas OAB gives mostly a 
psychological problem. A study evaluating the utility value among patients 
with OAB by using the Kings Health Questionnaire found an average utility 
value of 0.941, with a small range of 0.887 to 0.996 [29]. Another study that 
used EQ-5D found an average utility value of 0.85 for patients with OAB [7]. 
The utility value assigned in the present study for incontinence/no 
improvement was based on a study by Siddiqui et al., which in turn was 
based on a study on women with stress incontinence using the Health Utility 
Index 3 questionnaire [23]. We realize that this is not a true representation 
for OAB patients; however, to our knowledge no other relevant utility values 
are published. One-way sensitivity analysis using different utility values 
showed that employing a utility value of 0.85 or higher for OAB results in an 
unfavourable situation for starting treatment with SNM compared to 
starting treatment with BTX (e.g. ICER > €40.000).     
The present study gives an indication of the long-term financial burden from 
a societal point of view. However, the costs for surgery and for the devices 
may vary significantly between countries and even between hospitals within 
one country. Furthermore, there are inevitable differences from hospital to 
hospital in the management of idiopathic OAB with BTX and SNM. Sensitivity 
analysis shows that, in settings where all SNM patients are being tested with 
either PNE, bilateral PNE, bilateral TLP or when using Interstim 2 instead of 
1, starting with SNM treatment is not cost-effective. The main reason that 
the use of PNE test is not cost-effective is a result of its lower response rate, 
which in turn results into lower QALY value [13, 25]. Starting with SNM 
treatment is also not cost-effective under the scenario where the BTX 
procedure is performed under local anaesthesia, whereas SNM is not, or 
when both treatments are performed under local anaesthesia.  
Further (comparative) studies on the effectiveness and complication in the 
long-term, and their effect on the HRQL for both SNM and BTX, have to be 
conducted aiming to further assess the cost-effectiveness. 
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Conclusion 
In conclusion, starting with SNM compared to starting with BTX for patients 
with idiopathic OAB is cost-effective over a period of 5 years. However, in 
some scenarios, such as the use of local anaesthesia for BTX treatment and 
SNM PNE or bilateral test, SNM was not cost-effective. Further sensitivity 
analysis shows that more information is necessary to determine  whether 
the cost-effectiveness conclusion is still valid. Comparison studies of these 
two treatments options with respect to long-term effectiveness, 
complication rates and their effect on the HRQL are needed. 
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Since the late 1980’s when Tanagho et al. developed sacral 
neuromodulation therapy, continuing research has evolved this treatment 
into a minimally invasive, safe and effective treatment option for patients 
with chronic lower urinary tract dysfunction, including urgency incontinence, 
urgency-frequency, and non-obstructive urinary retention [1-4]. Currently an 
increasing number of patients are being treated with this therapy 
worldwide, including patients with faecal incontinence and constipation [5-
8]. 
 
This thesis has mainly focused on finding ways to improve SNM therapy 
among patients with urological indications.  
 
Battery improvement 
Patients presenting with pain at the implantation site and not being able to 
undergo an MRI scan are important issues for SNM therapy. In the 
satisfaction study half of the patients reported experiencing pain at the 
battery implant site. This corresponds with other publications [9, 10]. Not 
being able to undergo an MRI-scan is one of the most common concerns 
patients have with SNM therapy, and is often neglected by physicians. 
According to the guidelines of the manufacturer, the system is not MRI 
proof. Little is known about the consequences of undergoing an MRI-scan, 
so it is discouraged by the manufacturer. The basis for this policy is the 
potential hazards such as dislocation of the IPG and leads, heating of the 
leads and damage to the IPG. However, two recent studies reported 
reassuring results on patients with Interstim therapy that underwent 0.6 and 
1.5 Tesla MRI of brain, cervical spine and even the pelvis [11, 12]. In total 17 
patients were described and all but one showed no side effects or failures 
after MRI. Only the first patient in the Chermansky et al. study had an IPG 
failure. In this patient the magnetic switch on the IPG was not switched off 
[11]. This issue may be resolved as the manufacturer is designing an MRI-
compatible device. 
In 2006, Medtronic developed a smaller battery model, the Interstim II, 
which is just a little bigger than a 2 euro coin. Another improvement of this 
model is that there is no connection piece needed to connect the lead to the 
IPG, which could flip the IPG. This could reduce the incidence of pain at the 
IPG site, but there is not yet scientific data to confirm this. A disadvantage of 
the current IPG is that it is not rechargeable, so replacement is on average 
needed every 7 to 8 years for the Interstim I and 5-6 years for the Interstim 
II. Rechargeable devices could resolve this burden in the future.  
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Setting improvement 
Documentation about stimulation parameters (pulse width, amplitude and 
frequency) and their effect on the clinical outcome among urology patients 
is limited. The settings of the battery that is currently used are based on 
early animal models [13, 14]. In this thesis we have shown that changing the 
pulse rate (5Hz, 10Hz, 20Hz or 40Hz) could improve clinical outcome in some 
patients. Although no predefined setting could be demonstrated to work for 
all patients, no association was found with the type of complaint of the 
patient (OAB or urinary retention). It is currently unknown if this is inherent 
to the treatment or due to differences in patient characteristics or even lead 
position. In addition, pulse width could also play a role.  
Dudding and colleagues performed a similar study on patients with faecal 
incontinence [15]. Of 12 patients, 6 showed a subjective improvement after 
increasing the pulse-rate from 14 to 31Hz and 2 after lowering the pulse-
width from 210μs to 120μs. Lower frequency (7.5Hz) or higher pulse-width 
(450 μs) did not result in clinical improvement.  
A recent study among healthy cats showed that the optimal pulse-rate for 
achieving maximum inhibition of isovolumetric bladder contraction was 7.5 
and 10 Hz for stimulation at the dorsal penile nerve, the pudendal nerve and 
S1 sacral nerve, however only with relatively high intensity. Only stimulation 
of the dorsal nerve of the penis could also achieve similar results with 5 Hz 
and lower intensity [16]. A potential explanation for this is the more specific 
nerve stimulation due to convergence of afferent nerve fibres, when moving 
proximally from dorsal nerve of the penis to the pudendal nerve to the S1.  
 
Other stimulation sites 
With sacral neuromodulation, nerve fibres are stimulated that run in the 
vicinity of the third sacral foramen. It is still unknown which nerve fibres 
need to be stimulated for SNM to work and therefore the exact working 
mechanism of SNM is still a matter of speculation and theories. Recent 
studies with functional MRI and PET scans showed that sacral 
neuromodulation results in cortical changes in the brain presumably by 
stimulating the afferent nerve cells rather than the efferent nerve cells [17, 
18]. Current opinion on the mechanism of action is that SNM reorganises the 
spinal reflexes and regulates cortical activity [19]. Other approaches to 
stimulate these spinal reflexes and cortical activity are being tested. 
Pudendal nerve stimulation stimulates fibres that enter the sacral roots S2 – 
S3 – S4 [20-22]. Clinical results are encouraging and some researchers 
consider this as the rescue stimulation for SNM failures [20, 23]. 
Percutaneous Tibial Nerve Stimulation is another minimally invasive 
treatment that is currently under investigation. This treatment shows similar 
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short term results as SNM, however long-term studies are still lacking [24, 
25]. Another approach that can possibly be used in the future is the 
“laterograde” approach for stimulation at the level of the lumbar spine [26]. 
More studies on the PTNS and the lumbar spine approach would have to be 
conducted.  
 
Cost-effectiveness 
At the moment SNM and Botulinum toxin injection are two treatment 
options for patients with urgency incontinence or urgency-frequency who 
are refractory to conservative treatment. While both have similar short-term 
results, the initial and long-term costs are very different. This has led to 
studies comparing these two treatment options. Siddiqui et al. found that 
after 2 years Botulinum toxin treatment was more cost-effective than SNM 
[27]. This result was probably biased by a follow-up that was too short. In 
the cost-effectiveness study of this thesis, where we compared SNM to 
Botulinum toxin treatment, SNM became cost-effective after 4 years and 
continued to be cost-effective until the maximum follow-up period of 10 
years. A similar study by Arlandis confirms this result [28]. However, it 
should be noted that in our study this was only in the base case scenario 
(which includes both treatments being performed under general anaesthesia 
and the use of first stage tined lead test for SNM treatment) or when SNM 
was performed under local anesthesia while Botulinum toxin treatment was 
performed under general anaesthesia. For all other scenarios cost-
effectiveness was not shown.  
Even though SNM is cost-effective compared to Botulinum toxin therapy, 
further improvement of SNM is still needed. The costs would be less, for 
instance, if there are less adverse events and if the effectiveness could be 
increased due to patient selection  optimisation. Up to now, predictive 
factor studies for treatment outcome with sacral neuromodulation have not 
found an absolute predictive factor [29-31]. Trial stimulation is considered 
the only reliable way of choosing the right patients. Therefore trial 
stimulation is offered to every patient eligible for sacral neuromodulation 
before proceeding to the permanent battery implant. 
Psychiatric history has been thought to be a negative predictive factor [30, 
32]. However, recent studies show that psychiatric history is not so much a 
predictive factor for the effectiveness of the treatment but rather for the 
complication rate. Patients with a psychiatric history have a higher chance of 
developing a complication [10, 33]. 
Findings at the start of the treatment, such as the improvement rate or the 
amplitude and impedance of battery implant, might predict successful 
treatment outcome on the long run. 
General Discussion and Future Perspectives 
 109 
The long-term result study in this thesis shows that patients who had more 
that 90% improvement during the trial stimulation appear to have a greater 
chance of long-term success than those with 50-90% improvement. 
Ghazwani et al reported an association of high stimulation parameters 
(amplitude and impedance) at the time of implantation with loss of efficacy 
at the long-term follow-up [34]. 
 
Both urinary and faecal problems 
SNM is a treatment option for patients with urinary (urgency, urge-
incontinence and urinary bladder retention) and faecal (faecal incontinence 
and constipation) problems. While most patients have either a urinary 
problem or a faecal problem, some have both. Between 22-36% of patients 
with mainly urinary problems have additional faecal problems [35, 36]. In 
the satisfaction study among patients with urinary problems, one third had 
additional faecal problems, and almost half of them (47%) perceived 
improvement of their faecal problems. This corresponds with a recent study 
by Caremel et al., which found that of the patients with both urinary and 
faecal incontinence, and who were successfully treated with SNM for a 
predominant type of incontinence, 48.7% had an improvement in the other 
type of incontinence [37].  
SNM is possibly a good treatment option for patients with both urinary and 
faecal problems however, a long-term prospective study among this 
population group is lacking.  
 
Conclusion 
To conclude, even though sacral neuromodulation is an effective, minimally 
invasive and safe therapy for chronic lower urinary tract dysfunction, further 
studies are needed to improve patient comfort (new battery), efficacy 
(optimal stimulation parameters, possible new location of stimulation) and 
cost-effectiveness (predictive factors study, less adverse events).  
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Sacral neuromodulation (SNM) is an accepted treatment option for patients 
with idiopathic overactive bladder syndrome (I-OAB) or non-obstructive 
urinary retention and who are refractory to conservative treatment. Since 
FDA approval in 1997, an increasing number of patients have been treated 
with SNM. Chapter 1 provides an overview of the evidence behind SNM, 
based on the available clinical evidence concerning the efficacy and safety. 
Clinical studies have demonstrated its positive effect for the treatment of I-
OAB and non-obstructive urinary retention. The long-term success rate 
varies between 56 and 71% depending on the underlying bladder 
dysfunction. 
Patients considered eligible for SNM therapy are selected based on their 
response to a test period of SNM with an external neurostimulator. 
Currently two different methods are used to screen patients for their 
response to SNM: the Percutaneous Nerve Evaluation test (PNE) which uses 
a standard electrical wire electrode, and the first stage tined-lead placement 
test (FSTLP) which uses a special electrode with small anchors to reduce the 
risk of lead migration. In Chapter 2 a study is described in which the 
response rate of the FSTLP test to determine eligibility for SNM therapy was 
compared with PNE. In this single centre study patients with refractory I-
OAB or non-obstructive urinary retention, were screened with both PNE and 
FSTLP. Patients were followed prospectively and their response rate based 
on a bladder diary after PNE was compared to that after FSTLP. More than 
50% improvement in at least two relevant urinary symptoms was considered 
a positive response. One hundred patients were included (82 female, 69 I-
OAB). The mean age was 55 years (SD 13). The positive response rate on PNE 
was 47%. FSTLP showed a 69% positive response rate, which was negatively 
related to age. The 22% gain in positive response was statistically significant 
(p<0.001) and positively associated with female gender and younger age. 
Logistic regression analyses of the PNE results found no predictors for 
positive response. However, the same analysis for the FSTLP showed a 
negative effect of age. All 69 patients with a positive response to FSTLP 
received SNM treatment. Failure rate after an average of 2 years was 2.9%. 
This study suggests that FSTLP may be a more sensitive screening method 
than PNE to identify patients eligible for SNM therapy, warranting 
randomised trials.  
The implantable neurostimulator of SNM therapy can have a variety of 
settings. The waveform that the stimulator produces is a square wave pulse. 
The pulse-rate can be set between 2.1 and 130 Hz and the pulse-width 
between 60 and 450 µs. Furthermore, the amplitude can be changed from 
0.05 to 10.55 V. Chapter 3 describes a pilot study that evaluates the impact 
of pulse rate changes (5.2Hz–10Hz–21Hz–40Hz) in patients with suboptimal 
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response to SNM therapy on clinical outcome,  the sensory responses and 
SNM-related pain symptoms.  Fifty patients were included of which 40 (80%) 
were female. Mean age was 55.5 years (SD 12.3). Forty-one patients (82%) 
had I-OAB and 9 (18%) had chronic non-obstructive urinary retention. In this 
study no significant difference was found regarding clinical outcome (voiding 
diary and questionnaire) or the occurrence of SNM-related pain between 
the different pulse rates. On a group level, none of the four pulse rates in 
this study appears to have a significantly different effect on clinical outcome 
or SNM-related pain. However, a tailor-made approach for optimising 
treatment efficacy by changing the pulse rate appears to be useful. On 
individual basis, patients appear to benefit from changing the pulse rate for 
both treatment efficacy or stimulation related pain. 
In 2002, a new technique was introduced, which enabled percutaneous 
placement of a self-anchoring tined silicone lead also known as the tined 
lead procedure (TLP). This lead can be easily placed in the third sacral 
foramen under radiologic guidance. Short-term studies showed a decrease 
in the number of adverse events and the occurrence of lead migration with 
TLP. Chapter 4 describes a single centre study that assessed the long-term 
efficacy and adverse events of SNM with TLP. In this study 64 patients who 
received an implantable neurostimulator between 2002 and 2005 using the 
TLP technique were included. Mean follow-up was 53 months (range 35 to 
77). Five patients died of causes unrelated to SNM and they were not 
included in the analysis. The implantable neurostimulator was removed in 7 
patients. Furthermore, 3 patients stopped using the neurostimulator. 
Voiding diary analysis showed that 38 of 59 patients (64%) were successfully 
treated. There were 21 patients (33%) who underwent a surgical revision 
due to an adverse event and 1 (1.6%) who underwent lead revision because 
of suspected lead migration. This study shows that in the long-term SNM 
therapy with the TLP technique is a safe and effective treatment for patients 
with I-OAB or non-obstructive urinary retention. Furthermore, TLP appears 
to reduce the occurrence of lead migration but does not increase the long-
term success rate compared to data based on non-TLP technique. Patients 
who show more than 90% improvement during test stimulation appear to 
have a greater chance of long-term success than those with 50%-90% 
improvement. 
Most studies on SNM focus on clinical efficacy or on technique 
improvement. Impact on quality of life has been described, however, to a 
lesser extent and mostly evaluated with non-OAB or non-obstructive urinary 
retention-specific questionnaires. Because functional bladder disorders have 
a negative impact on the quality of life, evaluating patient satisfaction is also 
important as it may give an overall view on how the patients experience 
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their treatment on a daily basis. In Chapter 5 a study is described that 
evaluates the long-term satisfaction of patients with SNM therapy and their 
daily experiences with the treatment. All patients who received SNM 
therapy between 1990 and 2007 at our centre and who still have the 
implant received a postal questionnaire regarding their satisfaction and their 
experiences with the system. In total 275 questionnaires were sent, with a 
response rate of 75% (207). The population consisted of 83% females. Out of 
the total group 55% were being treated for I-OAB, 24% for non-obstructive 
urinary retention, 20% for a combination of I-OAB and retention and 1% for 
pelvic pain. Overall satisfaction with SNM was high (83%). Satisfaction was 
significantly and positively related to the patients’ perceived effect, number 
of pelvic floor co-morbidities, their view on yearly outpatient check-up and 
experience with the use of the patient programmer. No direct relationship 
was found with the patient’s age, sex, therapy duration, or type of complaint 
for which SNM treatment was offered. Forty-eight percent of the patients 
who had additional faecal problems before SNM treatment, experienced 
relief of their faecal problems. Despite the high satisfaction rate, regularly 
perceived pain or discomfort at the implant site was reported by 56% and 
40% of the patients, respectively. In total 10 patients report having regular 
pain at the implantation site. However 9 out of 10 also reported not 
requiring further treatment for it. Patients’ perceived limitations and 
concerns of SNM therapy were mostly related to MRI use, reimbursement 
and pregnancy.  
SNM and Botulinum toxin A (BTX) are two minimally invasive treatment 
options for patients with I-OAB. Chapter 6 is an overview of SNM and BTX 
treatment in the second-line management of adults with I-OAB, based on 
the available clinical evidence concerning the efficacy and safety. This review 
shows that both of these treatments have similar effectiveness rates and 
have relatively small, treatable and non-permanent side effects. BTX 
treatment has not yet been officially approved for urological disorders due 
to lack of long-term effect and safety data and lack of consensus regarding 
the proper dosage and the injection method. However, all BTX studies on 
patients with I-OAB are promising and point in the direction of approval. 
Until then, SNM is the only minimally invasive option approved for I-OAB 
patients who are refractory to conservative treatment.   
Besides clinical effectiveness, cost-effectiveness should also be considered 
when making a choice between SNM and BTX. Chapter 7 provides a cost-
effectiveness study comparing either starting treatment with SNM or BTX in 
patients with refractory I-OAB from a societal perspective. For this study 
information on the clinical effectiveness of the two treatments and on the 
course of the disease with the two treatments were based primarily on 
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published literature and, when required, on expert opinion. All costs were 
based on Dutch data from the year 2008. This study shows that starting with 
SNM resulted in a higher Quality Adjusted Life Years (QALY) gain (0.23 
difference after 5 years) and a higher cost (€6,428 difference) compared to 
starting with BTX, assuming both treatments were performed under general 
anaesthesia and for SNM treatment with FSTLP. The corresponding 
incremental cost-effectiveness ratio was €27,991/QALY. The probability of 
this ratio to be cost effective (e.g. under €40.000/QALY) is 88%. SNM starts 
to be cost-effective after four years. However, SNM was not cost-effective in 
some scenarios such as when BTX treatment was performed under local 
anaesthesia or when PNE or bilateral testing was used for SNM. 
Furthermore, sensitivity analysis shows that more information is necessary 
to determine whether the cost-effectiveness conclusion still holds. 
Especially, comparison studies of these two treatments options on long-term 
effectiveness, complication rate and their effect on the QOL are needed. 
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Sacrale neuromodulatie (SNM) is een geaccepteerde behandeloptie voor 
patiënten met een  idiopathisch overactieve blaassyndroom (I-OAB) of een 
niet-obstructieve urineretentie, die refractair zijn ondanks conservatieve 
behandeling. Sinds de FDA goedkeuring gaf in 1997, wordt een toenemend 
aantal patiënten behandeld met SNM. Hoofdstuk 1 geeft een overzicht van 
de wetenschappelijke onderbouwing van SNM, gebaseerd op de beschikbare 
klinische data betreffende de effectiviteit en veiligheid tot 2009. Klinisch 
onderzoek toonde een positief effect aan voor patiënten met I-OAB en niet-
obstructieve urineretentie. Het succespercentage op de lange termijn 
varieert tussen 56 en 71%, afhankelijk van het onderliggend blaaslijden.  
Patiënten die in aanmerking komen voor SNM, worden geselecteerd op 
basis van hun reactie op SNM via een externe neurostimulator, gedurende 
de testperiode. Momenteel worden er twee methodes gebruikt om 
patiënten te selecteren voor het wel of niet positief reageren op SNM: de 
Percutaneous Nerve Evaluation test (PNE, percutane zenuwstimulatie) die 
een standaardelektrode gebruikt, en een First Stage Tined-Lead Placement 
test (FSTLP) waarbij een speciale elektrode met kleine ankers gebruikt 
wordt, die de kans op onbedoelde verplaatsing van de elektrode 
verminderd, de zogenoemde elektrodemigratie. In hoofdstuk 2 wordt een 
studie beschreven waarin de reactie op FSTLP wordt vergeleken met PNE, 
om te bepalen welke van deze twee tests de respons op SNM het beste kon 
voorspellen. In deze single-centre studie werden patiënten met refractair I-
OAB of niet-obstructieve urineretentie gescreend door middel van beide 
methodes. Patiënten werden prospectief gevolgd en het effect op PNE, 
gebaseerd op plasdagboeken, werd vergeleken met dat van FSTLP. Meer dan 
50% verbetering van tenminste twee relevante symptomen werd 
beschouwd als een positieve reactie. Honderd patiënten werden 
geïncludeerd (82 vrouwen, 69 I-OAB). De gemiddelde leeftijd was 55 jaar (SD 
13). Het percentage met een positieve reactie op PNE was 47%. Bij FSTLP 
was dit 69%. De toename van de positieve reactie van 22% was statistisch 
significant (p<0.001) en positief geassocieerd met vrouwelijk geslacht en 
jongere leeftijd. Bij logistische regressieanalyse op PNE werden geen 
voorspellende waarden voor een positieve reactie gevonden. Dezelfde 
analyse liet zien dat hogere leeftijd een negatief effect had op het 
succespercentage van FSTLP. Alle 69 patiënten met een positieve reactie op 
FSTLP ontvingen SNMtherapie. Na een gemiddelde periode van 2 jaar 
hadden 2,9% van de patiënten geen reactie meer op SNM. Deze studie 
suggereert dat FSTLP een sensitievere screeningsmethode is voor de 
identificatie van patiënten die in aanmerking komen voor SNM therapie dan 
PNE. Verder gerandomiseerd onderzoek is echter noodzakelijk. 
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Er zijn verschillende instellingen mogelijk bij de implanteerbare 
neurostimulator. De door de stimulator geproduceerde impuls is een 
blokgolf. De pulsfrequentie kan variëren tussen 2.1 en 130 Hz en de 
pulsbreedte varieert tussen 60 en 450 µs. Verder kan de amplitude ingesteld 
worden tussen 0,05 en 10,55V. Hoofdstuk 3 beschrijft een pilotstudie bij 
patiënten met suboptimale reactie op SNM therapie, waarin de gevolgen 
van frequentieverandering (5.2Hz–10Hz–21Hz–40Hz) worden onderzocht op 
het klinisch effect, de sensorische reactie en SNM gerelateerde pijnklachten. 
Vijftig patiënten werden geïncludeerd waarvan 40 (80%) vrouwen. De 
gemiddelde leeftijd was 55,5 jaar (SD 12.3). Eenenveertig patiënten (82%) 
hadden I-OAB en 9 (18%) hadden last van chronische niet-obstructieve 
urineretentie. In dit onderzoek werden geen significante verschillen 
gevonden met betrekking tot de klinische effectiviteit (plasdagboek en 
vragenlijst) of tot de ontwikkeling van SNM gerelateerde pijn tussen de 
verschillende frequenties. Op groepsniveau toonde geen van de vier 
frequenties significant verschil met betrekking tot klinische reactie of SNM 
gerelateerde pijn. Desalniettemin zou, door de verandering van de 
frequentie, een individueel aangepaste benadering  voor het optimaliseren 
van de effectiviteit overwogen kunnen worden.  Op individueel niveau lijken 
patiënten namelijk wel voordelen te hebben met betrekking tot de 
effectiviteit en SNM gerelateerde pijn door de frequentie te veranderen.  
In 2002 werd een nieuwe techniek geïntroduceerd, die de percutane 
plaatsing van een elektrode met zelfverankerende siliconenhaken, genaamd 
tined lead procedure (TLP), mogelijk maakte. Deze elektrode kan onder 
radiologische begeleiding gemakkelijk in het derde sacrale foramen worden 
geplaatst. Kortetermijnstudies met TLP lieten een vermindering zien van het 
aantal elektrodemigraties en ongewenste complicaties. Hoofdstuk 4 
beschrijft een single-centre studie die de lange termijneffecten en 
complicaties van SNM met TLP onderzoekt. Vierenzestig patiënten die 
tussen 2002-2005 een implanteerbare neurostimulator door middel van TLP 
techniek ontvingen, werden geïncludeerd. De gemiddelde follow-up was 53 
maanden (range 35-77). Vijf patiënten overleden aan niet-SNM gerelateerde 
oorzaken, zij werden niet in de analyse geïncludeerd. Bij 7 patiënten werden 
de implanteerbare neurostimulatoren verwijderd en 3 patiënten stopten de 
behandeling op eigen initiatief. Plasdagboekanalyse liet bij 38 van de 59 
patiënten (64%) een succesvolle behandeling zien. 21 patiënten (33%) 
ondergingen chirurgische revisie wegens complicaties en bij één patiënt 
(1.6%) wegens verdenking op elektrodemigratie. Dit onderzoek laat zien dat 
op de lange termijn SNM therapie met de TLP techniek voor patiënten met I-
OAB of niet-obstructieve urineretentie veilig en effectief is. Verder lijkt TLP 
het aantal elektrodemigraties te reduceren. Vergeleken echter met studies 
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die geen TLP techniek gebruikten, is er op de lange termijn geen verschil in 
de effectiviteit van SNM te constateren. Daarnaast hadden patiënten die 
gedurende de testperiode een verbetering van hun klachten van meer dan 
90% in het plasdagboek vertoonden, een grotere kans op lange termijn 
succes vergeleken met patiënten die 50 tot 90% verbetering lieten zien 
De meeste studies over SNM bespreken de klinische effectiviteit of stellen 
technische verbeteringen voor. De invloed op de kwaliteit van leven wordt 
eveneens beschreven maar in mindere mate en vaak met niet–specifieke 
vragenlijsten voor OAB of niet-obstructieve urineretentie. Omdat 
functionele blaasaandoeningen een negatieve invloed hebben op de 
levenskwaliteit, is het evalueren van de patiënttevredenheid belangrijk. Het 
geeft inzicht in de dagelijks ervaringen van de patiënt gedurende de 
therapie. In hoofdstuk 5 worden zowel de lange termijn tevredenheid van 
patiënten gedurende SNM therapie als hun dagelijkse ervaringen 
beschreven. Alle patiënten die binnen onze afdeling tussen 1990 en 2007 
SNM therapie ondergingen en nog steeds een implantaat hebben, ontvingen 
een vragenlijst per post betreffende hun tevredenheid en ervaringen met 
SNM. In totaal werden 275 vragenlijsten verstuurd. De respons was hoog, 
aangezien 207 (75%) van de patiënten de vragenlijst retourneerden. 83% 
van de respondenten waren vrouwen, 55% werden behandeld voor I-OAB, 
24% voor niet-obstructieve urineretentie, 20% voor een combinatie van I-
OAB en retentie en 1% voor bekkenpijn. De algemene tevredenheid met 
SNM was hoog (83%). Tevredenheid was significant en positief gecorreleerd 
met het effect dat de patiënt had ervaren, het aantal 
bekkenbodemproblemen of aandoeningen van de bekkenbodem, hun 
instelling ten opzichte van de policontrolebezoeken, en hun ervaring met het 
gebruik van de afstandsbediening. Er werd geen directe relatie gevonden 
met de leeftijd of het geslacht van de patiënt, met het aantal jaren van 
behandeling, of met het type klachten waarvoor SNM geïndiceerd werd. Van 
de patiënten die bijkomende fecale problemen hadden vóór SNM, had 48% 
ook verbetering van deze klachten ervaren. Ondanks hoge 
tevredenheidspercentages gaven 56% van de patiënten regelmatig pijn en 
40% ongemak aan op de plaats van het implantaat. Negen van de tien 
patiënten die regelmatig pijn hadden, gaven aan geen behoefte aan 
pijnbehandeling te hebben. De meest voorkomende reden voor bezorgdheid 
en beperkingen door SNM waren gerelateerd aan MRI-gebruik, vergoeding 
en zwangerschap. 
SNM en Botulinum toxine A (BTX) therapie zijn twee minimaal invasieve 
behandelingsopties voor patiënten met I-OAB. Hoofdstuk 6 geeft een 
overzicht van de tweede lijnsbehandeling voor volwassenen met I-OAB, 
waarvoor gegevens werden gebruikt die evidence based zijn met betrekking 
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tot effectiviteit en veiligheid. Dit overzicht laat zien dat beide 
behandelingsmethoden een gelijkwaardige effectiviteit hebben en gepaard 
gaan met relatief milde bijwerkingen die goed behandelbaar en niet blijvend 
zijn. BTX therapie is tot nu toe nog niet officieel erkend omdat de lange 
termijn effecten en de veiligheid niet voldoende onderzocht zijn. Bovendien 
heerst er geen consensus over de juiste dosering en toedieningmethode. 
Toch zijn alle studies omtrent BTX bij patiënten met I-OAB veelbelovend en 
vormen een goede basis voor officiële registratie. Zolang er nog geen 
officiële registratie is voor BTX therapie, blijft behandeling met SNM de 
enige erkende minimaal invasieve behandelmethode zijn voor patiënten met 
I-OAB patiënten, die therapieresistent zijn voor conservatieve 
behandelingen.  
Naast het klinisch effect speelt ook de kosteneffectiviteit een rol bij de 
beslissing tussen SNM en BTX. Hoofdstuk 7 laat een 
kosteneffectiviteitsstudie zien waarin het starten met SNM- of BTX therapie 
bij patiënten met refractair I-OAB wordt vergeleken vanuit een 
maatschappelijk perspectief. Voor dit onderzoek werd de informatie over de 
klinische effectiviteit van de twee behandelmethoden en over het 
ziekteverloop primair gebaseerd op gepubliceerde literatuur en tevens, voor 
zover noodzakelijk, op meningen van experts. Alle kosten zijn gebaseerd op 
gegevens uit Nederland voor het jaar 2008. Deze studie laat zien dat het 
starten met SNM resulteert in hogere Quality Adjusted Life Years (QALY) 
winst (0,23 verschil na 5 jaar) en hogere kosten (€ 6.428,- verschil na 5 jaar) 
vergeleken met het starten met BTX, ervan uitgaande dat bij beide 
behandelingen algehele narcose werd toegepast en dat bij SNM de FSTLP 
techniek werd gebruikt. Het corresponderende incrementele 
kosteneffectiviteitsratio bedroeg € 27.991/QALY. De kans dat deze ratio 
kosteneffectief is (oftewel lager dan € 40.000/QALY) is 88%. SNM begint 
kosteneffectief te worden na vier jaar. SNM was niet kosteneffectief onder 
bepaalde omstandigheden zoals bij toediening van BTX onder lokale 
anesthesie, bij gebruik van PNE of bij de bilaterale test voor SNM. Verdere 
sensitiviteitsanalyse maakt duidelijk dat meer informatie nodig zal zijn om 
een definitieve uitspraak te doen over de betrouwbaarheid van de 
conclusies betreffende de kosteneffectiviteit in deze studie. Met name 
vergelijkende studies van deze twee behandelvormen met betrekking tot 
lange termijn effecten, complicatiepercentages en hun effecten op kwaliteit 
van leven zijn noodzakelijk.  
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Bij het schrijven van dit dankwoord komen er veel herinneringen naar 
boven. Er zijn veel mensen die bij hebben gedragen aan het tot stand komen 
van dit proefschrift, direct of indirect. Een aantal van hen wil ik hierbij 
expliciet bedanken:    
Prof. van Kerrebroeck, ik dank u dat u mij de kans hebt gegeven voor dit 
promotietraject en de steun die u daarbij gaf. Ik heb mij daardoor verder 
kunnen ontwikkelen als arts en wetenschapper  
Dr. de Wachter, beste Stefan. Toen je in Maastricht kwam werken, werden 
we tijdelijk kamergenoten. Ik herinner me nog goed de verwarring en 
grappige momenten die ontstonden tijdens onze gesprekken. Laten we 
zeggen: ik heb snel een aantal Vlaamse uitdrukkingen moeten leren. Ik dank 
je voor je begeleiding en ondersteuning, zelfs nadat je in Antwerpen bent 
gaan werken.  
Prof. de Bie, beste Rob. Het was steeds een genoegen om met je af te 
spreken. Je gaf me praktische ondersteuning en je gaf me altijd het gevoel 
dat het goed kwam. Uiteindelijk heb je gelijk gekregen. Ik dank je hiervoor.  
Terugdenkend aan mijn tijd als onderzoeker kijk ik met veel plezier terug aan 
de goede tijden die ik had met mijn collegaonderzoekers. Dennis, we hebben 
kort samen gewerkt, ik wil je bedanken voor het wegwijs maken in het 
wereldje van de Sacrale Neuromodulatie in Maastricht. Het team van 
‘caviaonderzoekers’: Rhea, Sajjad, Simone en Bart bedankt voor de 
gezelligheid zowel tijdens als na werktijd.  
Tom, mede-onderzoeker, paranimf en vriend. Toen ik vertrok, heb ik het je 
al gezegd: ik kan je niet genoeg bedanken voor de leuke tijd die we hadden, 
zowel in onze werkkamer (of moet ik zeggen: hokje) en daarbuiten. Ik mis 
het squashen, lekker eten (met of zonder satésaus) en films kijken.  
Micha, we hebben elkaar op de gang van onze afdelingen ontmoet en het 
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